The causes of antibiotic resistance are complex and include human behaviour at many levels of society; the consequences aff ect everybody in the world. Similarities with climate change are evident. Many eff orts have been made to describe the many diff erent facets of antibiotic resistance and the interventions needed to meet the challenge. However, coordinated action is largely absent, especially at the political level, both nationally and internationally. Antibiotics paved the way for unprecedented medical and societal developments, and are today indispensible in all health systems. Achievements in modern medicine, such as major surgery, organ transplantation, treatment of preterm babies, and cancer chemotherapy, which we today take for granted, would not be possible without access to eff ective treatment for bacterial infections. Within just a few years, we might be faced with dire setbacks, medically, socially, and economically, unless real and unprecedented global coordinated actions are immediately taken. Here, we describe the global situation of antibiotic resistance, its major causes and consequences, and identify key areas in which action is urgently needed.
producing extended-spectrum β-lactamase (ESBL), NDM-1, and Klebsiella pneumoniae carba penemase (KPC), indicates the ease with which resistance can spread. Findings of a study 8 done in New Delhi showed NDM-1-producing bacteria (including Shigella boydii and Vibrio cholera) in two (4%) of 50 drinking water samples and 51 (30%) of 171 seepage samples suggesting the possibility of acquiring resistance outside health-care facilities.
Quinolone antibiotics in particular are an example of misadventure. These drugs are synthetic and so do not arise in nature, yet 30 years after their widespread introduction resistance is epidemic. 9 More specifi cally, whole genome studies suggest that quinolone resistance was a crucial factor in the evolution of hospital MRSA. 10 Such examples of antibiotic-driven evolution go a long way to explaining present epidemics of resistant health-careassociated infections.
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In health-care settings, the spread of a resistant clone can be rapid and have severe consequences for vulnerable hosts. Carbapenem resistance among common Enterobacteriaceae has increased sharply over the past decade. In 2012, 4·6% of acute-care hospitals in the USA reported at least one health-care associated infection caused by carbapenem-resistant enterobacteria. The proportion of Enterobacteriaceae that were resistant to carbapenems increased from 0% in 2001 to 1·4% in 2010, with most of the increase recorded in Klebsiella spp. 1 Health-care associated infections are also increasingly recognised in LMICs. Findings of a recent review 12 showed that pooled prevalence of health-care associated infections in resource-limited settings (15·5 per 100 patients) was twice the average prevalence in Europe (7·1 per 100 patients). Incidence of infections acquired in intensive care units in developing countries (pooled density 47·9 per 1000 patient-days) was three times the rate in the USA (13·6 per 1000 patient-days). Health-care associated infections in neonatal intensive care units in some countries (15·2-62·0 infections per 1000 patient-days) are up to nine times more common than in the USA (6·9 infections per 1000 patient-days). Both the need for antibiotics and the burden of resistance are likely to increase with the rate of health-care associated infections in LMICs.
These trends are globally consistent. Hospital data from developing countries suggest that resistance to the WHOrecommended regimen of ampicillin and gentamicin in pathogens causing neonatal infections (in the fi rst 28 days of life) is common: 71% of isolates of Klebsiella spp and 50% of E coli are resistant to gentamicin. 13 Resistance is also a problem in early-onset, presumably maternally acquired, neonatal infections reported from hospital series in developing countries. 60-70% of E coli and nearly 100% of isolates of Klebsiella spp are ampicillin resistant, and 40-60% are resistant to gentamicin. 14 High rates of ESBL production in E coli have restricted the use of second-line treatment with extended-spectrum cephalosporins. 15 Many newborn babies in hospitals in south Asia are now treated with carbapenems as fi rst-line treatment for sepsis or presumed sepsis. Most worrying is the emergence of panresistant untreatable carbapenem-resistant Enterobacteriaceae and Acinetobacter spp infections associated with high mortality in neonatal nurseries. 16 In Pakistan, the emergence of pan-resistant bacterial isolates such as Acinetobacter spp and carbapenemresistant entero bacteria as causes of health-care associated sepsis in hospitals is rendering these infections untreatable. [16] [17] [18] 50-60% of community-acquired Gramnegative pathogens such as E coli associated with urinary tract infections have become resistant to common oral antibiotics (eg, amoxicillin, cefi xime, and ciprofl oxacin), complicating outpatient management.
Between July 2010 and August 2011, 72% of 1294 viable K pneumoniae isolates from sentinel sites in South Africa had antibiograms suggestive of ESBL production. 19 Compounding this problem is the emergence of several carbapenemase-resistance mechanisms. NDM-1 was fi rst detected in South Africa in September 2011, 20 and of 70 carbapenem resistant enterobacteria isolates from private and public hospitals received by the Antimicrobial Resistance Reference Laboratory between May and July 2013, 19 tested positive for NDM-1. 21 In India, E coli isolated from urine cultures of pregnant women in their fi rst trimesters in the community (n=1815) showed highest overall resistance to ampicillin, naladixic acid, and co-trimoxazole, as 75%, 73%, and 59%, respectively, between 2004 and 2007. 22 30% showed resistance to injectable antibiotics, such as aminoglycosides (represented by gentamicin). In a study of blood stream infections, 23 the proportion of E coli producing ESBLs increased from 40% in 2002 to 61% in 2009, and the proportion of K pneumoniae with carbapenem resistance increased from 2·4% to 52%.
Increasing rates of resistance to colistin and polymyxin B in Gram-negative organisms are being reported from countries around the world, including South Korea, 24 Italy, 25 Greece, 26, 27 and Saudi Arabia. 28 Moreover, there is some evidence of cross-resistance to colistin and host anti microbial peptides that are part of the body's immune response. 29 Hospital-acquired MRSA arises worldwide. In highincome countries, it is being tackled with a combination of new antibiotics and better hospital infection control, but community strains of MRSA continue to proliferate. 30 In LMICs such as South Africa, 52% of 1147 S aureus viable isolates from hospitalised bacteraemic intensive care unit patients were MRSAs. Gram-positive infections are less common in India, but high rates of MRSA in clinical isolates in various studies in India have been documented as 54·8% (range 32-80%). 31 In Pakistan, rates of MRSA have been fairly consistent since the mid-2000s at roughly 50%.
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duration of illness and higher rates of mortality in patients with resistant infections, increasing costs of treatment for resistant infections, and inability to do procedures that rely on eff ective antibiotics to prevent infection.
An estimated 25 000 people die every year in Europe from antibiotic-resistant bacteria. 34 In the USA in 2005, an estimated 94 000 invasive MRSA infections required hospitalisation and were associated with 19 000 deaths. 35 A recent report by the US Centers for Disease Control and Prevention conservatively estimated that at least 2 million illnesses and 23 000 deaths a year in the USA were caused by antibiotic resistance. 36 These estimates are useful for suggesting scale, but imprecise because resistant infections are more common in individuals on long courses of antibiotic treatment; it is diffi cult to ascertain whether resistance is the cause of death or a correlate of long antibiotic treatment, hospitalisation, and underlying sickness. Few reliable estimates are available for LMICs, but the higher burden of infectious disease and restricted access to new antibiotics suggest a higher burden than in high-income countries.
Findings of a study 37 of patients with bloodstream infections and pneumonia in 537 intensive care units in ten countries showed that the risk of death (hazard ratio) associated with antimicrobial resistance (additional to that of the infection) was 1·2 (1·1-1·4) for pneumonia and 1·2 (0·9-1·5) for bloodstream infections caused by bacteria resistant to ceftazidime (A baumannii or Pseudomonas aeruginosa), third-generation cephalosporins (E coli), and oxacillin (S aureus). Attributable mortality risk was highest for S aureus in both pneumonia and bloodstream infections. However, antimicrobial resistance did not signifi cantly increase length of stay. P aeruginosa caused the highest burden of health-care-associated infections because of its high prevalence and the pathogenicity of both its drug-sensitive and drug-resistant strains.
Multistate models, used to address the temporal dynamics of admission, infection, discharge, and death, have found that, compared with patients without S aureus bacteraemia, the death hazard was 5·6 times greater with MRSA (95% CI 3·36-9·41) and 2·7 times greater with meticillin-sensitive S aureus (MSSA) bacteraemia (95% CI 1·33-5·39). 38 After adjustment for comorbidity, hospitalisation, age, and sex, the death hazard was 2·9 times greater with MRSA (95% CI 1·70-4·88) and 1·7 times greater with MSSA (95% CI 0·84-3·47). A longterm follow-up study 39 of 2000 patients with S aureus or E coli bloodstream infections found an 80-150% increase in mortality associated with resistance at 30 days after infection. At 90 days, MRSA had twice the attributable risk of death relative to MSSA. 38 In LMICs, where the ability to pay for second-line drugs is limited, worse health outcomes, especially in neonates are more common. Even with eff ective antibiotics, infections are the major cause of neonatal deaths, which in turn account for more than a third of the global burden of child mortality. 13 More than half of neonates with ESBL sepsis can die (vs a quarter of neo nates with non-ESBL infections), and a half of neo nates with MRSA die (vs 21% of neonates with MSSA). 40 At these rates of mortality, roughly 106 514 neonatal deaths are attributable to Gramnegative organisms and S aureus, and 58 319 are attributable to ESBL resistance and MRSA in India alone.
In addition to the costs to human lives, high economic costs for health care exist, 41 and these resources could be deployed elsewhere. 42 Resistant infections are more expensive to treat and patients infected with resistant strains of bacteria are more likely to require longer hospitalisation and face higher treatment costs than are patients infected with drug-susceptible strains. 43, 44 According to one estimate, between 1997 and 1998, increases in drug resistance raised the cost of treating ear infections by about 20% (US$216 million). 45 Reduced Streptococcus pneumonia sensitivity to penicillin in many parts of the world has resulted in the need for more expensive antibiotics including fl uoroquinolones, oral cephalosporins, and macrolides, driving up the cost of treatment. In vitro resistance of S pneumoniae to β-lactams, macrolides, and other antibiotics has increased worldwide as a result of the global dissemination of a few pandemic clones. However, the most of roughly 826 000 pneumococcal disease deaths in children younger than 5 years likely result from poor access to antibiotics rather than drug resistance. 46 Although linezolid remains active against most Staphylococcus spp, resistance has emerged and is moving upwards. 47 Linezolid resistance has also been reported in Enterococcus faecium 48 and Enterococcus faecalis. 49 A third consequence of resistance is related to the inability to do other interventions such as surgery, transplantation, and chemotherapy. 50 Investigators of a recent study estimated that, without eff ective antibiotics, 30-40% of patients having total hip replacements would have a postoperative infection, with a case-fatality rate of roughly 30%. 51 This burden, although poorly quantifi ed, aff ects all countries and is likely to be the main way in which resistance drives up health-care costs.
Uses of human and agricultural antibiotics are increasing
Antibiotic use is a main driver of selection pressure that contributes to resistance, and because consumers do not understand this problem, the drugs are among the world's most commonly purchased. Most antibiotics are used unnecessarily, in commercially driven agriculture, and by physicians uncertain of a diagnosis or treating largely selflimiting bacterial or viral infections. In high-income countries, patients with resistant infections can turn to more expensive, newer-generation antibiotics, but in developing countries, where infectious diseases are common and the burden is high, patients might be unable to obtain or to aff ord second-line treatments.
Large diff erences in the frequency of resistant infections have been noted, both across European countries 52 and among regions of the USA. 53 , 54 Variations
The Lancet Infectious Diseases Commission in antibiotic consumption, both between and within countries, 52, [55] [56] [57] [58] [59] might explain the diff erences. Consumption of antibiotics in countries reporting data to the European Surveillance of Antimicrobial Consumption Network (ESAC-Net) in 2010 varied from 11·1 (Estonia) to 39·4 (Greece) defi ned daily doses per 1000 inhabitants per day. 60 Consumption of carbapenems increased in 15 Worldwide, antibiotic consumption is on the rise (fi gure 1). Although carbapenems are expensive, sales in Egypt, India, and Pakistan have increased with over-thecounter availability.
Non-prescription antibiotic use is common in many LMICs, where ensuring that people who truly need antibiotics have access while discouraging unnecessary use is a challenge. Non-prescription use accounts for 19-100% of antibiotic use outside northern Europe and North America. 61 Even when prescriptions are needed to obtain antibiotics, physicians might not adequately screen for appropriate use.
In Japan and the USA, patients drive expectations for antibiotic prescribing. In China, hospitals that rely on pharmaceutical sales for income have an incentive to overprescribe; one study 62 estimated that a quarter of revenue in two hospitals came from antibiotic sales. In India, doctors routinely receive compensation from drug sellers in exchange for directing patients to their pharmacies. Antibiotic sales increase with insurance status of patients because patients with insurance are likely to be less price sensitive. 63 Antibiotic prescribing might also be aff ected by competition between healthcare providers; in Taiwan, a one standard deviation increase in competition raises antibiotic prescription by up to 2·4%. 64 Competition from un sanctioned providers also exacerbates competitive pressure on legitimate medical professionals. Little evi dence exists that trained providers give more appropriate treatment than do untrained pharmacy attendants, perhaps because pharmacists often mimic prescription patterns of other local providers and unwittingly copy both desirable and undesirable practices. A study 65 from Thailand found that a pharmacy's proximity to a hospital improved the appropriateness of antibiotics sold.
Many drivers of antibiotic consumption are based in human medicine, but antibiotic use in veterinary medicine and for growth promotion and disease prevention in agriculture, aquaculture, and horticulture is also a major contributing factor. Although precise estimates are scarce, 
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of the crudely estimated 100 000-200 000 tonnes of antibiotics manufactured every year, 66 most goes to the agricultural, horticultural, and veterinary sectors. The fi nding of low levels of resistance in polar bears on the isolated Arctic archipelago of Svalbard supports the hypothesis that ecological resistance close to human settlements is anthropogenic in origin (fi gure 2). 67 Although the transfer of antibiotic resistance plasmids from treated animals to human beings has been long suspected, 68 fi ndings from recent studies using wholegenome sequencing have confi rmed animal-to-human transfers of resistance genes. 69 A global system for surveillance of antibiotic use and resistance and its health and economic burden is urgently needed. Surveillance should include environ mental sampling in addition to examination of clinical isolates.
Part 2: Getting out of the impasse
How did we end up here?
The lack of understanding of the unique features and risk of resistance has paved the way for the present epidemic. Moreover, few studies have been done on the magnitude of the burden to convince policy makers of the urgent need to react. Since the penicillin era, antibiotics have been viewed as wonder drugs that could be prescribed without fear of harm, despite early warnings of consequences such as antibiotic resistance and side-eff ects. 70, 71 Their use has spread into many nonmedical areas, and has been unregulated, both legally and illegally. Antibiotic resistance is perceived as a complex medical problem. Antibiotics are diff erent from all other drug groups in that the eff ects of their use extend far beyond individual patients. Even more worrying is the accumulating evidence that antibiotic use in seriously ill but uninfected patients can actually increase mortality. 72 Traffi c and selling of antibiotics at markets, shops, and pharmacies is largely unregulated, without prescription, and even without involvement of a person with pharmaceutical training. 61 This widespread access is made easier by the internet and marketing stunts for free or cheap antibiotics. Selective information and material incentives from pharmaceutical companies infl uence doctors in affl uent countries, leading to some regulation of their activities; however, with new markets emerging, more infl uence is to be expected in low-resource settings, which often do not have other sources of information and training. For instance, prescribers in Kisangani, the Democratic Republic of Congo, mentioned pharmaceutical companies as the fi rst source of information about antibiotics. 73 Production and use continues to increase generally in an uncontrolled way in developing countries. 74 In the non-medical arenas of agriculture, aquaculture, and intensive farming, huge amounts of antibiotics are used in some countries-up to four-times the amount used in human medicine. 75 There is little separation of the types of antibiotic used in human beings and animals.
Moving on National approaches and commitment
Countries that have implemented comprehensive national strategies have been the most successful in controlling resistance. [76] [77] [78] [79] These strategies include, but are not restricted to, good health-care infrastructure and health insurance for all; limited drug advertising; surveillance of antibiotic use and to detect resistance in human beings and animals; policies for prudent antibiotic use in human beings and animals; standardised infection control policies and suffi cient staffi ng; antibiotic stewardship programmes in hospitals and other health-care facilities; and isolation or de con tamination of patients with resistant organisms. 76 In particular, several European countries have introduced these strategies. Additionally, countries with cases of antibiotic resistance have found a targeted national approach successful-eg, the UK for control of MRSA and Clostridium diffi cile. 77 Israel controlled KPC by a national approach, 78 and the USA has implemented various initiatives. 79 However, these programmes need time and patience to be set up and need to be backed by visionary governments with adequate funding. A stepwise approach to a national strategy according to a contextualised and prioritised road map might be the best way forward for most settings. In resource-poor countries, there has been much less progress, although China and India notably have made important steps recently. A meeting of professional societies in India issued its Chennai declaration 80 and the Chinese Government has enacted policies to restrict antibiotic use, including the initiation of a campaign on antibiotic resistance, stratifi cation of antibiotic use, and enforced restriction on drug prescription. 81 Proposals for the stepwise development of activities of a national task force based on experiences from several LMICs are being developed by the Global Antibiotic Resistance Partnership (Ramanan Laxminarayan, Personal Communication). 
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Rational antibiotic use in hospitals
The set of activities and policies to improve the rational use of antibiotics is also known as antibiotic stewardship. Essential elements of an antibiotic policy include a stable and restrictive list of antibiotics in use, standard treatment guidelines, audit and feedback of prescriptions, surveillance of bacterial resistance and antibiotic use, and education at all levels. 82 Antibiotic stewardship has typically been developed in the hospital context in resource-rich countries, but stewardship activities should be expanded to primary care on a national level. Its combined goals are improved outcomes for patients, containment of antibiotic resistance, and increased cost-eff ectiveness of care. Antibiotic stewardship should be done by all health-care facilities and should be part of accreditation programmes.
Eff ective stewardship programmes can decrease antibiotic use by 20-40%, incidence of health-careassociated infections (C diffi cile, MRSA, and others), lengths of stay, and prevalence of bacterial resistance. 83, 84 Ideally, steward ship teams should include an infectious diseases physician, a (clinical) pharmacist with infectious diseases training, a clinical microbiologist, information system specialist, infection control professional, and a hospital epidemiologist, but such specialists might not be available. 85 Barriers to the implementation of eff ective and sustainable programmes exist in many regions of the world. The bottlenecks for implementing stewardship in both resource rich and poor countries are often strikingly similar, largely as a result of insuffi cient leadership, commit ment, and funding. Standard treatment guidelines, which are essential to steer the use of antibiotics, can be counter productive if not updated regularly and well implemented. National guidelines, particularly in LMICs, if present, are often outdated or not disseminated to the genuine prescribers, who in turn might use a combination of outdated textbooks, international but locally irrelevant guidelines, or just the habits of their teacher. 86 Concentrated eff orts at national levels are needed to invest in the revision of standard treatment guidelines into clear, simple, updated, evidence-based, locally relevant, and accessible docu ments. A recent national project launched in Vietnam has, as one of its objectives, the development of updated guidelines for several important infectious disease syndromes. 87 Establishing the resistance threshold for particular infections warranting the switch to an alternative empirical antibiotic is a particular challenge. 88 
Rational antibiotic use in the community
A programme on rational antibiotic use or antibiotic stewardship in the community should cover a wide range of settings, such as ambulatory care facilities, pharmacies, drug vendor outlets, households, and agriculture. Overuse and irrational use of antibiotics, either driven by the supply or demand sides, have been documented in all these settings. 89 On the supply side, physicians are often role models for other health professionals and patients who learn how to use antibiotics from their prescriptions. 2 Apart from medical training, physicians are infl uenced by their peers, and perceived demands of patients. Therefore, physicians might fi nd it diffi cult to comply with treatment guidelines. 90 These barriers to compliance should be removed or minimised, and options for alternative actions for guideline compliance should be simultaneously provided. 91 Examples of options for nonantibiotic treatment in viral or self-limiting infections are the prescription of herbal medicines, as opposed to antibiotics, 92 and use of a delayed prescription technique with explicit instructions for patients about when to use antibiotics. 93 To encourage guideline compliance, consequences of irrational use of antibiotics should be reframed to be relevant to the self-interest of prescribers and institutions. Motivational measures include pay-forperformance policy, 92 the audit-feedback mechanism on antibiotic prescribing rates of individual prescribers, 94 and public disclosure on antibiotic prescribing rates of each health-care facility or area. 95 Major challenges arise when antibiotic prescriptions are a source of revenue for individuals or institutions, either by a fee-for-service remuneration scheme 96 or drug-promotion incentives. 97 In this case, a combination of the audit-feedback and the public disclosure measures seems to be useful. However, in many resource-poor countries, doctors own the pharmacies and, therefore, the fi nancial incentives to prescribe expensive antibiotics are even greater than with a fee-for-service reimbursement. In these settings, separation of prescription and dispensing activities are needed. On the demand side, self-medication by consumers with antibiotics purchased without a prescription is common, especially in eastern and southern Europe, Africa, South America, and Asia. 61 Consumers have positive attitudes towards antibiotics, but paradoxically they have poor knowledge about these drugs and diseases. 98 The availability of antibiotics without prescription-an important enabling factor-mainly results from absence of prescription-only regulation, ineff ective law enforce ment, poverty-driven practice, culture, and norms. 99, 100 Sub optimum compliance on use, including taking leftover antibiotics from previous treatment courses and sharing unused drugs with other people, is common in both developed and developing countries. 101 Improvements in health-care fi nancing might positively aff ect access to a full course of antibiotics.
Ideally, consumers should have access to accurate information on antibiotics and infectious diseases instead of access to antibiotics without prescription. A ban of over-the-counter sale of antibiotics has been implemented in many countries including Chile. For countries with inadequate health delivery systems, prescription-only regulation might impede access to antibiotics. Although regulation is crucial to safeguard access to antibiotics, a transition towards such regulation needs governmental commitment and improvements in health systems that are not possible in many countries. Hence, antibiotic stewardship programmes need to be adjusted to local conditions-eg, use of telemedicine to help with treatment decisions and the referral process 104 and to help community pharmacists make good decisions about antibiotic dispensing. More research is needed on how to balance the eff ects of specifi c interventions on individual health versus increasing the resistant bacterial population. In low-resources countries, stewardship programmes to empower drug vendors on rational use of antibiotics seem promising, but further research is needed. 105 
Education and changing social norms
When irrational use of antibiotics repeatedly happens among the public and health professionals, it becomes the norm. To break this pattern, antibiotic stewardship programmes should focus not only on appropriate use, but also on ensuring sustainability of behavioural change and reorientation of social norms. 92, 106 Such a stewardship programme in an LMIC is the Antibiotic Smart Use Program in Thailand. 92 Many bottlenecks remain in the promotion and sustainability of good prescription practices, especially with regards to social norms. Solutions need to focus on multifaceted and multilevel interventions that defi ne local barriers and beliefs, which can vary widely between cultures, countries, and regions.
Education of all health-care workers, laboratory staff , veterinarians, and the public on appropriate antibiotic use and antibiotic resistance is essential, and educational strategies have recently been reviewed. 107 Although education alone might not be powerful enough as an intervention, it generates knowledge that is essential for health-care workers to understand and support the resistance control programmes; such education should be started very early in the medical curriculum. 107 The role of up-to-date undergraduate and postgraduate education is even more important in settings with restricted access to medical literature.
Clear information for policy makers about antibiotic resistance and its eff ect on public health has a crucial role in making this complex problem tangible; initiatives such as the Drug Resistance Index might help to achieve this. 108 Educational and awareness campaigns for the general public might help to generate an understanding that can support the prescriber to withhold antibiotics. 109 Although hard endpoints are diffi cult to defi ne and to measure, these campaigns seem to contribute to more careful use of antibiotics. Education should be tailored and started early on to shape behaviour rather than having to change it.
Infection control
Better than treatment of infection is, of course, prevention. From a resistance perspective, prevention reduces antibiotic use and the spread of resistant bacteria; however, prevention is not the main strategy to control resistance because antibiotic use also needs to be controlled. Nevertheless, at the community level, improvement of sanitation, access to clean water, poverty reduction, and vaccination will have a huge eff ect on both infectious disease incidence and transfer of and colonisation with resistant genes and multidrug-resistant organisms.
At the hospital level, prevention of health-care-associated infections, which are often multidrug resistant, is essential, but challenging. Besides hand hygiene, the importance of which cannot be overemphasised, benchmarking (open comparison of between health-care facilities) of frequencies of health-care-associated infections is useful to decrease the number of these infections. Observation makes one more careful; most of the infection control policies in place have been developed around MRSA, vancomycin-resistant enterococci, C diffi cile, catheter-related bloodstream infections, catheter-associated urinary tract infections, and ventilator pneumonia. Infection control interventions need to be reassessed and improved in an era with multidrugresistant Gram-negative bacilli and mobile antibiotic resistance genes. Additionally, cultural barriers for implementation of basic hygiene procedures are probably a widespread problem and need much more study.
Role of diagnostics
Eff orts to improve microbiological laboratories are underway. Speed of testing and laboratory automation have been the focus of recent developments. In trying to reduce testing time, various methods have been developed (eg, PCR-based tests, various point-of-care tests, and MALDI-TOF mass spectrometry). These tests are supplementary to detect disease-causing pathogens next to traditional culture-based methods because they detect only the pathogens for which the test is designed. 110, 111 Diagnostic methods that reduce antibiotic use or narrow the spectrum should be promoted. Even if these methods do not have a direct benefi t on clinical outcome, reduction of antibiotic pressure can help to slow induction and spread of resistance. [112] [113] [114] Besides direct care of patients, the results of diagnostic microbiology testing are used to inform local, regional, and national surveillance systems. A successful example is the signifi cant reduction in MRSA bacteraemia in hospitals in the UK since implementation of mandatory MRSA surveillance in 2001. 115 Surveillance of bacterial resistance generates essential information, which promotes and directs stewardship activities. The scarcity of quality-assured microbiology laboratories in lowresource settings and lack of priority given in the past decades to sustained bacterial surveillance have led to large empty areas on the worldwide resistance maps, especially for sub-Saharan Africa and rural Asia.
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Quality-assured basic microbiology services and routine bacterial resistance surveillance are urgently needed in most of these areas. Positive experiences in high-income settings, such as Europe, 117 with its easy-to-understand, interactive, and yearly updated data, could inspire policy makers in other regions. The addition of antibiotic resistance to death registers might help to raise awareness of antibiotic resistance on the priority agenda of policy makers.
Beyond use in human beings
Bolder interventions outside hospitals and a move to ecological antibiotic stewardship are needed. Strategies should be focused on control of non-human sources of antibiotics, resistant bacteria, and resistance genes, such as agriculture and waste water from the pharmaceutical industry. The issue of antibiotic resistance should be part of the one-health movement. Use of antibiotics as growth promoters should be banned worldwide as has happened in the EU. In Denmark, the banning of growth promoters in livestock resulted in a net reduction of animal antibiotic use with no or minor increases in production costs without increased incidence of zoonotic infections in human beings. 118 Worryingly, last resort drugs, such as colistin, are being used extensively in agriculture. 119 Recent initiatives, also in the EU, are trying to limit the use of this drug in agriculture.
The environment is key in the spread of resistance. For example, wastewater treatment facilities can be a hotspot for horizontal resistance gene transfer (fi gure 3). 120 Strategies to reduce this mode of transfer are warranted, including neutralisation of antibiotics in wastewater and in the environment generally. Findings from a recent study 121 showed that chlorination of drinking water can actually concentrate some antibiotic resistant genes. Research eff orts need to focus on how to reduce and neutralise manmade antibiotic pressure and how to control the resistance gene pool in hotspot environments.
Research
Research eff orts need to be focused on intervention strategies and solutions rather than doom-and-gloom reports. Until recently, MRSA and vancomycin-resistant enterococci governed the resistance agenda, but now, multidrug-resistant Gram-negative bacteria are the main cause for concern. However, fi ndings (summarised in the recent Cochrane reports 122 and elsewhere) show that community and hospital anti biotic stewardship interventions can modulate pre scription enough to reduce resistance in many organisms in some settings. Timeseries analysis can be used by all hospitals with computerised databases of antibiotic consumption and resistance rates. This approach allows interventions to be tailored to individual scenarios and prediction of resistance rates, and this information can be used to develop local treatment guidelines.
Besides antibiotics, new treatment strategies under investigation include methods to stop plasmid replication 123 or resistance mechanisms such as effl ux pump inhibitors. 124 Furthermore, bacteriophage treatment-used in the 1920s and later in the Soviet era-is being investigated as another potential strategy, but regulatory requirements for these types of drugs are challenging, 125 and their use might not extend to life-threatening infections.
Safeguarding the future
Will any set of interventions be eff ective enough, in view of the present wave of antibiotic resistance? Suggested interventions are not optional, they are basic requirements to ensure rational use of antibiotics and optimum outcomes for patients. Enlightened national and global leadership is needed along with suffi cient technical capacity at all diff erent policy levels. Comprehensive national and international plans, like those in the EU, 126 are needed, and should have similar visibility and eff ect to those for other important health problems such as HIV, tuberculosis, and malaria. Additionally, these national plans need to take into account their interfaces with health-care organisation, quality assurance and fi nancing, and professional education. The scientifi c community should clarify the causes, scale, and fast pace of the evolution of resistance. Antibiotic resistance should be on the global political agenda, not just the agendas of infectious disease meetings.
Emphasis is placed on reinvigoration of the drug discovery industry, but there is a sense that all low-hanging fruit have already been picked and that new developments, even if successful, cannot sate demand and will be only a temporary fi x. Many people believe that with billions of years of evolution, bacteria will always be better genetic engineers than people. Antibiotics are a natural product of bacteria and so resistance mechanisms are not new. Therefore, antibiotics are a precious public good and their intended and unintended environmental release needs to be monitored and controlled.
Stewardship eff orts might win a battle, they will certainly not win the war. Antibiotic stewardship-an
The Lancet Infectious Diseases Commission integral part of standard care provision-should be part of hospital accreditation. Besides, a holistic, ecological, one-health approach is needed. There is an urgent need to stop enriching the resistance gene pool with unnecessary antibiotic pollution. The issues of antibiotic resistance are akin to those of global warming due to excess use of carbon-based fuels with the resultant pollution, and we need a worldwide agenda, perhaps like the Kyoto agreement, but with much more adherence. 127 Solutions will not be easy and, paradoxically, might include increasing the price of antibiotics to put a true value on their use, while maintaining the delicate balance between overuse versus lack of access. There is room for innovative ideas in quality assurance, health fi nancing, and social marketing.
The future of antibiotics and survival of every human being that acquires a bacterial infection will depend on the serious commitment of many stakeholders, including government authorities, policy makers, health-care workers, university teachers, pharmaceutical companies, and consumers.
Part 3: Minimising the time to eff ective treatment-rapid diagnostic testing Diagnostic uncertainty drives irrational use
Diagnostic (viral or bacterial cause) or prognostic (lifethreatening or self-limiting infection) uncertainty makes it diffi cult for clinicians to know when to provide and when to withhold antibiotic treatment. Consequently, antibiotics are overused in hospitals and outpatient settings, resulting in increased antibiotic resistance 52 and the pandemic spread of highly resistant bacterial clones. 128 Findings of studies of patients with acute cough-one of the most common reasons for consultation in primary care and antibiotic prescription in high income countries-showed that antibiotics did not meaningfully change important outcomes. 129, 130 Since the early days of discovery of bacteria, culture-based assays have remained the gold standard for identifi cation of pathogens and susceptibility testing. However, these methods are slow, typically identifying causative pathogens in at best 24 h, and returning susceptibility results in 48 h. Minimisation of time to eff ective treatment decreases morbidity and mortality in severe infection. 131 The eff ects of antibiotic resistance on human health are probably highest in countries with the lowest income because the spread of resistant bacteria is facilitated by poor hygiene, contaminated food, polluted water, overcrowding, and increased susceptibility to infection because of malnutrition or HIV. Personalised medicine based on novel and rapid diagnostic strategies should help identify patients who need antibiotics. In many such settings, the need for alternative technologies is also pressing, because routine culture and susceptibility testing are not provided, even to support diagnosis of lifethreatening infections like pneumonia and meningitis (fi gure 4). 132 Immunoassays provided a faster option, but the potential for changing the landscape of diagnostic testing became clear with the development of the PCR in the 1980s. 133 Since then, we have seen a technological revolution with the development of many complex, highly specifi c molecular diagnostic assays. These systems can decrease the time needed for detection of biomolecules, like proteins and nucleic acids, from a few hours to a few minutes, and should greatly improve medical diagnostics. However, most of these technologies have not yet reached clinical diagnostic laboratories.
Defi ning the medical needs
Many available rapid diagnostic tests are designed on the basis of microbiological grounds and detect as many microbes as possible, rather than on clinical grounds to address the real medical need. Furthermore, no consensus exists on how quickly tests should produce results to identify patients who really need an antibiotic-should companies only invest in developing technologies that produce results in less than 30 min in primary care or less than 1 h in hospital care? If so, very few companies have technologies in their pipelines that can meet these requirements. So should a fi rst dose of antibiotics be given and then treatment adjusted on the basis of diagnostic test results?
How do the needs (eg, speed, robustness of system, cost, and user friendliness) in industrialised countries compare with those in lower resource settings? And how will these needs fi t with the diff erent health-care models and reimbursement systems? Should companies develop tests that identify pathogens and detect resistance, or is the identifi cation of which organisms caused the infection not important as long as doctors know which antibiotics are needed? Which antibiotic resistance genes are always expressed in vivo and could therefore be targeted in the system? Quantitative microbial cultures with cut-off s (expressed in colony forming units per mL) are used to distinguish between colonisation and infection, but should technologies be developed that also defi ne molecular load thresholds (expressed in number of DNA copies per mL) to distinguish the colonisation and infection status of potential pathogens in diff erent types of samples? How should diagnostics be used in clinical trials to identify patients infected with targeted pathogens or multidrugresistant organisms? Many companies are struggling to align their business goals with the technology solutions because these fundamental questions have not been properly addressed by experts in the specialty. A technology road map on rapid diagnostic tests for infectious diseases is needed to help forecast, plan, and coordinate technology developments that meet real medical needs.
Huge technical challenges
Molecular tests can reduce the time to yield results but come with many drawbacks, including complex sample preparation, little integration of the diff erent steps, inability to handle large volumes or multiplexing for
The Lancet Infectious Diseases Commission detection of many diff erent targets, and high cost. Ideally, so-called sample-in to results-out technologies are needed that integrate sample preparation, amplifi cation, detection, and analysis. The system should be able to detect pathogens and host biomarkers (proteins and nucleic acids) simultaneously. Sample preparation remains the largest bottleneck in miniaturised diagnostics: 134 large volumes (several millilitres of blood) need to be reduced to small amounts (in the order of microlitres); the microbial load in the sample can vary a lot and be very low; the target should remain intact, but many complex specimens contain nucleases or inhibitors of nucleic acid amplifi cations. Therefore, most sample preparations of available miniaturised molecular systems rely on many operations, and need several liquid additions and washing steps.
Most microfl uidics-based systems rely on conventional benchtop sample preparation, thus restricting their use in point-of-care tests with limited or no laboratory access. Conversion of these off -cartridge sample preparation steps to cartridge-based microfl uidic systems will be challenging because the microscale physical conditions (eg, the surface/volume ratio) can alter the assay conditions. Additionally, the reliability and cost of lab-on-a-chip systems typically increase with a factor per added component, such as fl uidic interfacing, valving, pump ing, microscale mixing, and waste disposal. Although microfl uidics off er great promise in the area of rapid diagnostics, a microscale assay needs to be carefully designed, in which novel solutions should provide integrated functionalities in a minimum amount of unit steps and in a minimum cartridge size. Finally, most rapid diagnostic tests are based on detection of nucleic acids, but several other technologies are being pursued (eg, impedance and magnetic resonance) and several national and global initiatives are supporting the development of these new technologies.
Lack of guidance for assessments
Few guidelines for the assessment of clinical diagnostic tests for infectious diseases exist. Companies often claim sensitivities and specifi cities close to 100% without oversight on the design and conduct of the diagnostic assessments. Moreover, these values are calculated with spiked or archived samples, and are not indicative of the real-world situations in which tests will be used. Other factors often not taken into account (eg, conditions of storage and shelf life) are also important, especially in LMICs. 135 If standards are available for the assessment of diagnostic tests, they are published in industrialised countries and are not necessarily applicable to diseases prevalent in other settings. 136 Finally, few studies investigated rapid diagnostic tests in terms of eff ect on antibiotic use or resistance, or patients' outcomes.
Poor performance of molecular tests
Despite excellent analytical sensitivity and specifi city, the test might perform poorly in clinical trials or routine use, depending on study groups (screening vs diagnosis, symptomatic vs asymptomatic, active vs latent infection), setting (low vs high prevalence), com plexity of test (done by trained vs unskilled staff ), and comparator (more or less sensitive than the comparator test). Assessment of molecular tests has been mainly analytical and few were extensively assessed with clinical specimens from clearly defi ned populations of patients from a wide geographic area. Findings from multicentre studies showed signifi cant variations of detection rates of molecular tests between laboratories, with diff erent or even the same tests, even though some of the laboratory personnel were very experienced with the use of amplifi cation assays. 137, 138 Standardisation of methods and reference reagents is needed for complete quality assessment programmes, including profi ciency panels to assess the performance of molecular tests. A network of designated diagnostic laboratories that can assess molecular tests, alongside routine diagnostic testing, would be a step forward.
No proven clinical benefi t
Assessment of the quality of molecular tests should take clinical usefulness into account. However, diagnostic tests are sold and used without good evidence of eff ectiveness, especially in developing countries, and the endpoints that should be used in clinical trials have not been agreed upon. Very few well designed preclinical and clinical trials have been done to show that rapid diagnostic testing improves clinical outcome or reduces antibiotic resistance. Although more recently, clinical trials on the performance and eff ectiveness of diagnostic tests were funded by the public sector (eg, the European Commission's Framework Programmes), most trials are still sponsored by the No studies have assessed the best integration of tests into health-care practice. The danger is that novel and expensive technologies could become representative of high-quality care with little evidence to support their use. Technological innovations that allow more personalised medicine are likely to raise rather than lower health-care costs. A McKinsey report 139 estimated that four countries (Austria, Portugal, Spain, and the USA) would spend more than 20% of their gross domestic product on health care, and only fi ve of 21 Organisation for Economic Cooperation and Development countries (Denmark, Italy, the Netherlands, Sweden, and the UK) would spend less than 15% by 2040. The USA would allocate nearly 30% of its economic output to health care by 2040. Therefore, if new technologies are to be successfully implemented, we will need to move away from the business-as-usual approach, to develop new and smarter pathways of care, and to show that they are cost-eff ective.
What samples should be used?
No consensus exists on the best sampling sites for detection of pathogens in many infectious diseases. Good studies comparing diff erent specimens are scarce or results inconsistent. Most of these studies are based on conventional diagnostic microbiology and cannot be extrapolated to molecular diagnostics. For example, acute community-acquired respiratory tract infections are the commonest reason for the prescription of antibiotics. However, we do not know what the best specimens are to detect many of the pathogens causing respiratory tract infections, or how to distinguish between organisms infecting the lower respiratory tract and those colonising the rhinopharynx (eg, nasal aspirate, nasopharyngeal aspirate, nasal swab, nasopharyngeal swab, nasal wash, oropharyngeal swab, or sputum). Depending on the organism, distinct diff erences are seen when comparing diff erent specimens by use of conventional diagnostic microbiology. 140 However, with more sensitive molecular methods, such as nucleic amplifi cation systems, the diff erences in recovery rates between the respiratory specimens might be more subtle.
Role in antibiotic stewardship is controversial
Over the past decade, the prevalences of infections caused by ESBL-producing and carbapenemase-producing Gramnegative bacteria have increased signifi cantly. 128 A rapid assay that can detect infection with such organisms should improve outcomes for patients because delay in initiation of eff ective anti microbial treatment tends to be associated with increased mortality. 131 However, whether rapid diagnostics for detection of genetic resistance markers are useful to guide treatment remains controversial. First, the available molecular assays are not truly rapid diagnostic systems because many of them require bacterial DNA as a template and hence, are heavily reliant on conventional culture. 141 Second, whether susceptibility tests are enough or whether laboratories should still seek ESBLs and carbapenemases directly is unclear. 142 Third, limited data suggest an association between minimum inhibitory concentrations (MICs) and outcomes for patients with Gram-negative infections. 143 Hence phenotypic testing based on MIC values might guide antimicrobial treatment better than do genotypic tests that detect the resistance mechanism. If the susceptibility test results (susceptibility category or MIC, irrespective of resistance mechanism) should guide treatment, molecular assays for detection of ESBLs or carbapenemases might have little value for management of infected patients. For infection control purposes, these assays could still be very useful in the detection of carriers and prevention of transmission.
Many barriers for use
Research needs to move beyond comparison of point-ofcare test performance with laboratory tests to an agenda of understanding barriers and opportunities regarding uptake into routine care. Despite fi ndings from several studies showing that simple and user-friendly tests for detecting C-reactive protein 144 and procalcitonin 145 are eff ective in achieving important reductions in antibiotic prescribing, these tests are still not widely used. Many barriers, including physicians' attitudes towards diagnostic testing, approval by regulatory authorities, recommendation by guidelines, social, ethical, economical, and political factors, aff ect the uptake of new diagnostic technologies and delivery into health systems. Many countries, especially in low-resource settings, do not regulate in-vitro diagnostics or require submission of clinical trial data. 136 Input and help from behavioural sciences and social marketing are needed to address barriers to acceptance of rapid diagnostic tests and to help understand motivational factors that could help to overcome hurdles to eff ective use of these tests in management of patients.
Guidelines de-emphasise diagnostic microbiology
Many guidelines do not recommend conventional diagnostics to identify the pathogens or they recommend treatment initiation within a short timeframe (eg, treatment of community-acquired pneumonia), leading to excessive empirical treatment with broad-spectrum antibiotics. 146 Additionally, in developing countries, where access to diagnostic laboratories is limited, patients presenting with a particular syndrome are treated for all major causes. Although generally cheap, this approach results in inappropriate antibiotic treatment without syndromic diagnosis of disease. Rapid diagnostic tests for detection of causative agents or biomarkers at the point of care are needed to allow prompt and specifi c targeting with a narrow-spectrum antibiotic. Rapid diagnostics would boost development of narrow-spectrum antibiotics because companion diagnostics are a prerequisite to the prescription The Lancet Infectious Diseases Commission of these drugs. Improved diagnostics would also reduce the cost of clinical trials by enabling focused enrolment of only those patients infected with target pathogens.
Part 4: The interface between people and animals
Antibiotic use in animals
Use of antibiotics in animals and its potential eff ect on human health has been a controversy for at least half a century, presently fuelled by the crisis of resistance. Predictably the debate is polarised. Results of scientifi c studies have sometimes been confl icting, which is confusing for readers unfamiliar with the context. Although the discussion here is restricted to terrestrial animals excluding honeybees, aquaculture is also important in the overall discussion.
Use for growth promotion
The growth-promoting eff ect of low doses of antimicrobials was discovered in the late 1940s. 147 Feeding subtherapeutic doses of antimicrobials became an integral part of intensive rearing of animals. Undoubtedly, these practices supported the intensifi cation of modern food production by facilitating early weaning, increased animal densities, and cheap feed sources. 148 Furthermore, suboptimum growth caused by unsanitary conditions is sometimes compensated with addition of antibiotics to feed. 148 Worldwide, many substances have been or are used, some of which are not used in human medicine (eg, fl avophospholipol) and some from classes that are (eg, the macrolide tylosin). How these substances lead to increased growth rate is unclear, but prevention of enteric diseases, such as weaning diarrhoea, probably has an important role. 148 Low doses of tetracycline also reduces morbidity and increases growth of premature children. 149 Where authorised, antibiotics used for growth promotion can generally be purchased over the counter without veterinary involvement. In many countries, growth promoting use of several antimicrobials is authorised and widely practised. In the EU, restricted authorisation of antimicrobial types began several decades ago. On the basis of recommendations by a committee chaired by Professor Michael M Swann, the UK withdrew authorisation for growth promotion of several substances including tetracyclines and penicillin in 1971. 150 The EU and neighbouring countries followed suit in the 1970s. Sweden banned the all use of antimicrobials for growth promotion in 1986, and Denmark, Finland, and Norway abandoned all such use in the late 1990s. 151 Finally, all growth promoting use was abandoned in the EU in 2006. In the USA, the Food and Drug Administration (FDA) has released draft guidelines on judicious use of antimicrobials in the rearing of animals for food production. These recommendations aim to reduce the overall use of medically important anti microbials and include veterinary oversight and consultation. If this guidance is adhered to, a gradual phasing out of growth promoting use is to be expected.
The eff ect of low doses of antimicrobials for growth promotion on antimicrobial resistance has been documented for several substances. 152 For example, use of the glycopeptide avoparcin was associated with the selection of vancomycin-resistant enterococci; 153 after its withdrawal, the prevalence of resistance decreased. 154 
Veterinary use
Generally, the most common indications for anti microbial treatment or preventive use in terrestrial animals reared for food production are enteric and respiratory disorders in young animals and mastitis in dairy cows. 155 Untreated, these disorders aff ect animal welfare and productivity and can sometimes lead to substantial mortality. Therapeutic use can include individual animals, but can also be treatment of a group of diseased animals by injection or orally. Preventive use can be anything from targeted interventions to control the spread of a diagnosed disease in a defi ned group of animals to routine treatment of all animals during specifi c periods of stress such as weaning, after transportation, or when combining new animals with a herd or mixing animals from diff erent sources. Preventive use is mostly given via feed or water. With some exceptions, the antimicrobial classes used are the same as those used in human medicine. However, some newer types of antimicrobials, such as carbapenems, oxazolidinones, and glycylcyclines are not used for animals reared for food.
Regulations and practices vary widely around the globe and are probably aff ected by the economic and social context. In the EU, all antimicrobials for systemic use in animals reared for food production are on prescription only. In other parts of the world, antimicrobials for treatment might be on prescription, whereas some products indicated for prevention are not. In other areas, regulation and capacity to supervise can be very weak. The World Organisation for Animal Health (OIE) provides guidance and capacity building, especially in those areas.
Data for amounts of antimicrobials sold for or used in animals are still scarce in most regions of the world. The network for European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) was formed by the European Medicines Agency on request by the European Commission to collect comparable data for consumption of antimicrobials for animals in the EU. Only data aggregated for all animal species are collected. To correct for diff erences in animal populations over time and between countries, a population correction unit was developed, roughly equal to the estimated live weight of the animal population in each country. Data for 2011 suggest substantial diff erences in amounts sold in participating countries. 156 Many factors might explain this fi nding, including a blunt unit of measurement and diff erences in com position of the animal populations and systems for production and disease profi les between countries. Furthermore, many of the participating countries have only recently set up systems for data collection and at least a couple of years are probably needed to establish a good baseline. However, other explanations must exist, such as diff erences in ways to prevent diseases and prescription behaviour. In most countries, products are mostly intended for medication of groups of animals via feed or water. Overall, tetracyclines, sulphonamides, and penicillins were the main classes sold. In the EU, monitoring of resistance in commensals from healthy animals are reported to the European Food Safety Authority; when fi gures on sales of antimicrobials are compared with fi gures on resistance-in E coli to tetracycline, for example-countries reporting lower sales also report lower prevalences of resistance. 156, 157 However, because the use of antimicrobials varies between animal species and even between production systems, further associations between sales and resistance are hampered by the dearth of sales data by animal species. A process aiming to set up systems for harmonised collection of sales data by species and to develop more refi ned units of measurement is underway within ESVAC.
Complex pathways
The interface between human beings and animals is complex; numerous possible pathways exist for transmission of resistant bacteria. The fact that resistance genes can be transferred between diff erent commensal bacterial species and from those to pathogens adds to the complexity. Exposure through food is the most commonly studied transmission route and the most important. The most likely source of resistant bacteria in food of animal origin is contamination from animals' intestines during slaughter, but there are numerous other stages in food production where contamination with microbes, or amplifi cation or reduction of their numbers, can happen (fi gure 5). Furthermore, exchange of resistance genes between bacteria from diff erent sources can happen at all stages, including in the kitchen. 158 Food is traded internationally, which means that local production does not equal local consumption. Epidemiological studies of food-borne transfer of antimicrobial resistance sometimes generate confl icting results. Less explored are potential environmental routes. 159 Manure and biological solids applied to land might contain both antimicrobials and resistant bacteria. Through run-off from fertilised land or directly from sewage, contamination of surface water can also occur. Spread to human beings and animals is possible through contact with soil, irrigation of crops, contact with water, or with wildlife.
Evidence of spread
Direct spread of MRSA from animals to people in close contact is well documented. 160 Transfer of community or hospital-associated MRSA from people to animals has also been reported. 160 Food-borne transmission of non-typhoid salmonella and of campylobacter from animals is well established and arises whether bacteria are resistant or not. 161, 162 More recently, handling or consumption of contaminated poultry meat has been implicated as a source of E coli causing urinary tract infections in women. 163 Less understood is transfer indirectly via the environment. After land application of manure, salmonella and campylobacter will survive for some time in soil, depending on the environmental conditions. 164 Contamination of vegetables and other crops directly from soil or through irrigation with contaminated water is a possible but poorly documented route of spread.
Direct evidence of spread of resistance genes between the microbiotas of various animal species and people is diffi cult to obtain, and the precise routes of spread more diffi cult to discern. However, indirect evidence clearly suggests that such transmission does happen. Findings from an early experimental study 68 showed spread of an E coli multiresistance plasmid between chickens and from chickens to people in contact with the animals. On a population level, studies of dissemination of genes conveying resistance to antimicrobials used in animals but not in people or vice versa provide strong indications of the direction of spread. In former East Germany, a streptothricin antimicrobial was introduced for growth promotion in 1983. Shortly after the introduction, a streptothricin-resistance gene carried on a transposon was recorded in E coli from pigs. Subsequently, the resistance gene appeared in E coli from farmers, their family members, from urinary tract infections of urban citizens, and later also in salmonella and shigella isolated from cases of diarrhoea in people. 153 Another example of putative spread is the gene aacC4. This gene conveys resistance to apramycin, gentamicin, and tobramycin in Enterobacteriaceae. Apramycin is an aminoglycoside used only in animals, mostly mixed in feed. The gene aacC4 gene has been identifi ed in E coli and Salmonella enterica serotype Typhimurium (S typhimurium) from animals and their environment, but also to a limited extent in people. 165 The detection of vancomycin-resistant enterococci with the vanA-gene cluster in animals in the EU triggered The Lancet Infectious Diseases Commission several investigators to explore possible transfer from animal to human enterococci. Although some types of the gene cluster are found only in people, an overlap has been reported between types found in isolates from animals and from human beings. 153 In an experimental study, Lester and colleagues 166 showed transfer of the gene cluster from ingested animal to human enterococci in the intestine of three of six healthy volunteers not receiving antimicrobials. Thus, transient carriage of animal-derived commensals can result in transfer of resistance genes to bacteria likely to be better adapted to human hosts.
The most challenging question hitherto is to what extent animals contribute to the spread of genes conveying ESBL or plasmid-mediated AmpC-type enzymes. Because ESBL and AmpC production can be conveyed by many diff erent genes, which can be carried on diff erent plasmids, many possible permutations exist. Occurrence of E coli producing various ESBLs or AmpC in companion animals, horses, and animals reared for food production is increasingly reported. 167 In several studies, isolates from animals or food products have been compared with isolates from human beings in the community or in hospitals. In a study from the Netherlands, 168 20% of the isolates from people carried any of the two most commonly occurring plasmidgene combinations occurring on broiler meat on the domestic market, suggesting transmission via food. By contrast, in a study from Sweden, 169 the overlap between the plasmid-gene combination that dominates in broilers raised in that country was rare in clinical isolates from human beings. The reasons for the diff ering results are not known, but various context-specifi c factors along the farmto-fork chain might be implicated-eg, diff erences in amounts and types of antimicrobials used in broiler production.
An investigation of the temporal patterns of occurrence of various genes conveying ESBL or AmpC-production suggests that in many cases, emergence in human medicine seems to pre-date emergence in various animals. For example, CTX-M-15 is one of the most commonly reported ESBLs in human beings worldwide, but is rarely reported in animals reared for food production. 167 By contrast, CTX-M-15 is commonly reported from wild birds. 159 At least some of the genes conveying ESBL or AmpC might originally have been introduced in various animal populations from human carriers, maybe through environmental routes. If so, they have subsequently been spread between animals, farms, and regions leading to the present situation. Recent occasional fi ndings of carbapenemases in Enterobacteriaceae originating from animals reared for food production 170 might also be explained by introduction from other sources. Carbapenems are not authorised for use in animals, but through the use of any β-lactam or other antibiotic to which the carrying bacteria is resistant, these genes can now be amplifi ed through co-selection and spread in animal populations.
The eff ect
A direct eff ect of emergence and spread of antimicrobial resistance in bacteria of animal origin is the loss of eff ectiveness of antimicrobials used for treatment of animals. This aspect is poorly documented, but without eff ective treatment of serious diseases, mortality and morbidity would increase with negative eff ects on animal welfare. In the rearing of animals for food production, there would also be consequences for productivity and economy. These eff ects are not limited to intensively reared animals. In LMICs, infectious diseases in animals can have a substantial eff ect on the economy of a local community dependent on small-scale rearing of animals. 155 Eventually, the spread of resistance could lead to a local food security problem with negative eff ects on public health.
More studied, and far more controversial, is the potential eff ect of spread of bacteria and resistance genes from animals on public health. Guidance for risk assessment of food-borne antimicrobial resistance has been agreed by the Codex Alimentarius Commission. 171 A full quantitative risk assessment in this area requires large amount of data including relevant endpoints, such as public health burden of resistance. Because of the many possible routes of transmission and the complexity of resistance epidemiology, diff erent attempts to estimate the risk have yielded quite diff erent results. Environ mental aspects could be taken into account in risk assessments related to antimicrobial resistance. 152, 172 Models made with such an approach could provide a more holistic understanding of the importance of diff erent eff ects of use of antimicrobials and in the identifi cation of the most crucial control points. WHO has developed a list ranking antimicrobial classes according to their importance for public health. Two criteria were used: whether the drug is the sole treatment or one of few alternatives to treat serious human diseases, or used to treat diseases caused by organisms that might be transmitted via non-human sources or might acquire resistance genes from non-human sources. Antimicrobials that meet both these criteria are classifi ed as critically important. The WHO list can be used to support decisions about data collection, risk assessment, and risk management. To further support allocation of resources, WHO has prioritised critically important anti microbials: fl uoroquinolones, third and fourth generation cephalosporins, and macrolides are viewed as the highest priority for risk analysis. 173 Although the exact eff ect of transfer of resistance genes or bacteria in any given context remains diff use, food borne pathogens and MRSA are spread from animals to people. Strong circumstantial evidence suggests that resistance genes circulate between people, animals, and the environment. Any further increase in prevalence among animals will increase the likelihood of spread to other realms. Additionally, even rare transfer events could have a substantial eff ect if secondary amplifi cation takes place in hospitals and the community. 174 Veterinary medicine and agriculture need to apply antimicrobial stewardship to curb further emergence and spread of antimicrobial resistance in the sector.
Time to move on from blame and shame
The use of antimicrobials for animals reared for food production remains controversial. Knowledge gaps in the understanding of the broader resistance dynamics, confl icting results in various studies, and in particular the diffi culty quantifying the potential eff ect on public health are important barriers for change. This situation has led to a polarised debate, in which some state that the eff ect is small, while others argue that there is major harm.
Policies vary between countries and regions, and are not restricted to antimicrobials for animals, animal health and welfare, and food safety. Food is traded globally and other factors such as economic, export, and trade policies can play a part, as can consumers' expectations of access to aff ordable quality food products. Interests in these areas might well be confl icting, and this is important to acknowledge in the debate and in decision making.
General guidance spanning regulatory needs and prudent use of antimicrobials is provided by all international organisations: the OIE, WHO, and the UN Food and Agriculture Organization (FAO). Imple mentation of prudent use relies on the daily work of farmers and veterinarians. Legitimate confl icting interests can surround this implementation-eg, production economy and the ethical obligation to care for diseased animals. In view of the polarised debate, veterinarians and farmers might feel that they are blamed for a problem they perceive is essentially generated by medical doctors. 175 This situation might lead to a defensive attitude and does not cater for productive solutions. A way forward would be to acknowledge that human health, animal health, and the environment are all interlinked, and that the responsibility for dealing with the problems of resistance is shared by all stakeholders. Strong local and global partnerships are needed in which policy makers, academia, and professionals from all sectors work together to improve present systems. The common goal should be to preserve the eff ect of antimicrobials for future generations of human beings, but also for animals. Antimicrobials should only be used when needed. In the case of animals, this means that growth promotion and routine prevention with antimicrobials also used for treatment should be phased out, as recommended by the Swann Committee. 150 When needed, antimicrobials should be used judiciously. Furthermore, long-term eff orts are needed with a focus on reducing the need for treatments by improving infection control and management and by developing robust systems.
Part 5: The access and excess dilemma A global balance
To tackle antibiotic resistance needs not only a renewal of the depleted pipeline of novel antibacterial drugs, but conservation of those now in use. A failure to do so might lead to rolling back major achievements in modern medicine. 176 Because resistance inevitably follows antibiotic use, the paradox is that populations-both in industrialised countries and LMICs-can face challenges of access and excess. Even in high-income countries, antibiotic use ranges widely, with three times greater outpatient consumption in Cyprus than in the Netherlands. 177 The evidence points to increasing use of antibiotics in hospitals over time, much of it not consistent with clinical guidelines. 122 Although some patients are prescribed unnecessary courses of antibiotics, others are not given appropriate treatment.
This challenge is one of access and rational use, as defi ned as "how to ensure that when [patients] need drug therapy the appropriate drug is prescribed for them, it is eff ective and of acceptable quality and safety, it is available at the right time at a price they can aff ord, it is dispensed correctly and it is taken in the right dose at the right intervals and for the right length of time". 178 With this defi nition in mind, challenges associated with access of antibiotics begin with a recognition of the right to health, but result from therapeutic, fi nancial, and structural barriers. Therapeutic access refers to the bottlenecksscientifi c and fi nancial-in bringing new antibiotics to market. Financial access characterises the diffi culty in aff ording a rational course of antibiotic treatment, and structural access addresses the obstacles to delivering antibiotics eff ectively in the system and using them rationally at the clinical level in-country. Each of these barriers to access need to be surmounted if an antibiotic is to progress from bench to bedside. These barriers are also shown in the so-called glocalisation of antibiotics (ie, how a global product integrates into local markets). Delays in the entry of novel antibiotics-and delays in the availability of complementary technologies like diagnostics or vaccinescan aff ect the access and use of antibiotics in a local market.
Importantly, excess or overuse also contributes to problems of antibiotic access. Antibiotics are overused for many reasons, including patients' expectations of prescribed treatment; information asymmetry at the user, prescriber, or provider levels; diagnostic uncertainty; and the many fi nancial incentives for overprescription, all of which drive both presumptive and unnecessary use of antibiotics. The excessive use of antibiotics traces, in part, from the revenues their use generates for health systems and health-care providers. In China, the dispensation of drugs comprises a substantial part of provider incomes, and data from 28 cities reveal a prescription rate of antibiotics twice that recognised as appropriate by WHO. 179 Such fi nancial incentives exist at all levels of the system, from pharmaceutical companies to procurement agencies, retailers, prescribers, and dispensers, and include the informal market.
Strategic points for intervention
From bench to bedside, strategic points for intervention exist to address access and excess in antibiotic use. The
The Lancet Infectious Diseases Commission interaction among prescribers, dispensers, and patients is central in this value chain. However, surrounding this chain is a health-care delivery system with many points at which policy leverage might positively or negatively aff ect access to antibiotics. 180 To balance access and excess requires recon ceptualisation of the delivery of antibiotics as a complex adaptive system. The interaction between the components of such a complex system is non-linear. Product, information, and fi nancing fl ow through the value chain of pharmaceutical delivery of antibiotics. Adequate regulation of these fl ows through the value chain can balance access and excess use of antibiotics in the delivery system. The value chain includes multifaceted innovation, dis semination and introduction of new techniques, technology, and rules, scaling up and implementation of these approaches, and then assessment and monitoring of their eff ect on access and excess of antibiotics.
Innovation in tackling antibiotic resistance
With the dearth of novel antibiotics, scientifi c bottlenecks in the research and development pipeline need to be overcome, from identifi cation of promising leads and crossing from basic and translational research to improvement of clinical trials without sacrifi cing safety and targeting reimbursement. 181 To ensure access, but not excess, investment in research and development should be unlinked from returns. Measures such as extended data exclusivity and premium pricing are not the answer. Such approaches tie revenues to volume-based sales, and worse yet, higher prices place access to those in need at risk. Alternatively, public funding could be conditioned to buy out patents. Manufacturers could then be licensed to produce antibiotics on a scale appropriate for rational use. 182 Innovation is needed, not only for the development of new antibiotics, but also for combination therapy. Of course, there is the synergistic action of using drugs in combination, such as trimethoprim and sulfamethoxazole in co-trimoxazole, amoxicillin, and clavulanic acid, or even perhaps someday silver with some antibiotics. 183 However, there is also the reality that if the probabilities of resistance to drugs A and B are independent, then the chances of developing resistance to both drugs used together will be much less likely-the product of those probabilities. 184 By targeting many mechanisms of resistance simultaneously, combination therapy might help slow the emergence of resistance. 185 Innovation is also needed for technologies complementary to novel antibiotics. Preventive vaccines can reduce the need for antibiotic treatment, 186 but better diagnostics can both accelerate the recruitment of patients with multidrug-resistant infections into clinical trials and narrow the use of new antibiotics once on the market. As a method to hold resistance in check, the potential of diagnostics might be underused. Diagnostics in the USA guide 60-70% of health decisions, but might account for only 2% of health expenditures. 187 The health-care expenditure on diagnostics in LMICs is similarly low. 188 Product development partnerships like the Foundation for Innovative New Diagnostics (FIND) and Partners Advancing Transitions in Healthcare (PATH) have made important contributions to bringing diagnostics suited to low-resource settings to market. Notably, FIND supported the development of the GeneXpert MTB/RIF system, which not only identifi es patients with smear-positive tuberculosis, but also establishes resistance to rifampicin from untreated sputum samples in less than 2 h. 189 Product profi les for point-of-care testing that returns susceptibility results in hours, not days, can provide a road map for targeted grand challenges in diagnostics research for bacterial pathogens.
The assessment of syndromic management and the clinical algorithms based on existing diagnostic methods have to complement the development of new diagnostics. A clinical algorithm now allows community health workers to make a presumptive diagnosis of acute lower respiratory infection, but had a better diagnostic been available, unnecessary treatments might have been avoided. 190 Even where access to such technologies exists, distrust in the quality of diagnostics, the paucity of timely results from diagnostic tests, and the fear of poor outcomes, can prompt clinicians to set aside diagnostic test fi ndings. Improved diagnosis-part technology, part syndromic management-can reduce uncertainty about whether to treat with antibiotics or not. Taken to scale, the advent of simple diagnostic tests for yaws and trachoma could help reduce the need for mass administration of antibiotics, such as azithromycin. [191] [192] [193] Improved diagnostics can help convert a vicious cycle into a more virtuous one.
Dissemination and introduction of antibiotic treatment
Antibiotics, costing as little as $0·13 to $2·03 per patient, could save an estimated 509 000 lives from newborn sepsis and pneumonia every year. 194 In fact, fewer than a third of children with suspected pneumonia in LMICs receive potentially life-saving antibiotics (such as amoxicillin provided twice daily for 3-5 days) for treatment. The gap between children younger than 5 years who receive treatment and those who do not can be quite pronounced when a comparison is made between the top and bottom quintile of households on the basis of wealth. 195 By contrast, antibiotics are too often prescribed for diarrhoea when oral rehydration salts and zinc would better serve patients. 196 Access to such treatment contributes to growing community-wide drug resistance. In higher income countries like the USA, overuse of antibiotics for upper respiratory infections not only persists, 197 but is also implicated in the widespread use of broad-spectrum antibiotics, for patients treated in ambulatory care. 198 The increased risk of drug-resistant infection further decreases the clinician's threshold to prescribe antibiotics more often and with broader spectrum, thereby feeding a vicious cycle. In some places and over the internet, antibiotics can be obtained without prescription.
199 Worse yet, substandard 
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antibiotics may be ineff ective but still contribute to drug resistance. For those living on less than $1 per day, upfront purchase of a complete course of antibiotics might be beyond fi nancial reach, and adherence to a full course of prescribed antibiotics is unlikely. Access to antibiotics is not just a matter of innovation in product development; even for existing drugs delivery may be wanting, especially in resource-limited settings. For example, data from a study in Tanzania 200 suggested that Gram-negative sepsis in children was associated with a mortality rate double that of malarial infection. Nearly half the neonates with Gram-negative sepsis at a tertiary hospital in the Mwanza region had infections resistant to third-generation cephalo sporins. However, almost all of the Gram-negative enteric bacteria were sensitive to meropenem, a drug too expensive and often unavailable in many LMICs. 201 Narrowly framed interventions aimed at dissemination and introduction of antibiotics and their rational use might focus exclusively on health-care providers in hospitals and clinics (fi gure 6). This narrow view has focused past eff orts on prescription audits and provider training. Stewardship implies both eff ective treatment of patients with antibiotics and minimisation of collateral damage from the use of these drugs. A meta-analysis of studies 122 of antibiotic steward ship programmes suggested approaches that restrict prescription of antibiotics had larger eff ect than did persuasive approaches, but that over time, the diff erences were not statistically signifi cant. Even if some multifactorial interventions under study seem more promising than others, one approach is unlikely to suit all settings. Metaanalyses can incorporate publication bias that comes from not reporting negative fi ndings and thus fail to capture the underlying heterogeneity of study settings. 94 Eff ective antibiotic stewardship eff orts, however, need broader control over product, information, and fi nancing. The fl ow of antibiotic product is in the system might be controlled by restriction of formularies, requirement of preauthorisation of antibiotic use, and de-escalation of broad-spectrum coverage when a pathogen is identifi ed. Prospective audits with intervention and feedback, education of patients, guidelines for providers, and computer-assisted strategies aff ect the fl ow of information in the system. Approaches such as off ering a safety-net antibiotic prescription for otitis media and instructing parents not to fi ll the prescription unless symptoms worsen or do not improve after 48 h, might help set the default option in favour of rational use. 201 Such an approach involves re-engineering the process by which health care is delivered. Additionally, checklists-perhaps through antibiotic order forms, computer order entry, or infectious disease consultant approval-can ensure more rational use of antibiotics. 202 The appropriateness of these approaches is context-dependent and might diff er between LMICs and higher income settings.
From bench to bedside, there are both fi nancial and nonfi nancial incentives and aff ects on decision-making.
Incentives do not consistently align in a way
Another strategic point of intervention might be in procurement of antibiotics, in which innovative approaches can provide access and prevent excess. For example, the facilitation of the supply of second-line treatment for multidrug-resistant tuberculosis. Such treatment can be 50-200 times more expensive than fi rst-line treatment. The Green Light Committee reviews applications and provides technical assistance to countries seeking drugs to treat multidrug-resistant tuberculosis. Companies provide these drugs at concessionary prices through the Green Light Committee process, with the assurance that the drugs will be used appropriately and in a way that minimises resistance. 
Scale-up and implementation
Breakthrough approaches to solve the access and excess dilemma will need the integration of antibiotic stewardship programmes into health-care delivery systems. Without such vision, stewardship programmes might remain experimental or pilot interventions without substantial eff ect on antimicrobial resistance or access to life-saving treatment.
An eff ective new diagnostic test for bacterial acute lower respiratory infections could save at least 405 000 children's The Lancet Infectious Diseases Commission lives per year. 190 For example, the value of a rapid diagnostic test for malaria in the setting of fever will vary by local prevalence of the disease, by seasonal changes, and by how often another cause of fever, like pneumonia, might coincide with a positive malaria diagnostic test fi nding. Local context matters. However, when such testing protocols are applied, do health-care providers adjust to the context? Evidence from the scientifi c record on the eff ect of diagnostic testing on prescription behaviour is mixed. 204, 205 The increased prescription of antibiotics in the setting of a negative rapid diagnostic test fi nding for malaria might lead to improved rational use, or it could just result in overprescription of antibiotics as compensatory behaviour to mollify patients' expectations of treatment. 206 In the health-care delivery system, antibiotic steward ship might be through integrated community case management. Applied to malaria, diarrhoea, and pneumonia, this strategy includes community health workers in the management of uncomplicated childhood illness and the referral of more complicated cases. Factors, ranging from how compatible pro grammes are with local sociocultural beliefs to how secure supply inventories of drugs and diagnostics are, can aff ect the introduction of integrated community case manage ment. 207 In a study in Burkina Faso, Ghana, and Uganda, 208 community health workers were taught to use rapid diagnostic tests for malaria and to count the respiratory rate to diagnose pneumonia. Although com pliance with the test results was high and unnecessary use of artemisinin combination treatments curbed, varying degrees of both antibiotic overuse and underuse were noted. After a simple clinical algorithm, community health workers in rural Zambia used rapid diagnostic tests with few adverse events, reliably dispensed artemether-lumefantrine for malaria and amoxicillin for pneumonia, and eff ectively managed their supply of medicines. 209 The dispensing of antipyretics to children with negative results of rapid diagnostic tests also seemed to help meet caregiver expectations.
Bridging the divide between individual and collective action will also be key. The misuse of antibiotics confers risks upon the individual, not just the wider community. These risks include the selection of resistant and more virulent infections, opening the door to opportunistic fungal infections, and leading to subsequent, more drugresistant rounds of bacterial infections. Similar trends can be seen at the organisational level. Is there a failure of collective action when no individual insurer will invest in infection control at a local hospital, in case other insurers free-ride off that investment? Nor will any individual drug company show self-restraint in marketing an antibiotic when its therapeutic competitors do not. Collective action will need new forms of partnerships, such as pooling of the insured risks for infection control at a hospital.
Antibiotics are not just part of routine episodic care in the prophylaxis and treatment of bacterial infections. As the experience of population-wide campaigns such as ivermectin treatment for onchocerciasis has shown, removal of the barrier of drug costs alone is not suffi cient to ensure delivery. 210 In scaling-up this programme to reach 25 million people every year in Africa, Merck acknowledged that this donation needed complementary investment to train health-care workers to integrate such eff orts into the delivery system. 211 Most notably, the campaign to eradicate trachoma has come to rely on one dose of azithromycin, although this is part of a larger SAFE strategy, including surgery for trichiasis and advanced disease, facial cleanliness to reduce trans mission, and environmental improve ments. In addition to ready-to-use therapeutic food, fi ndings from a recent study 212 support the routine use of antibiotics as a part of the management of severe acute malnutrition, which claims 1 million children's lives every year.
A policy tension might arise between saving lives with short-term mass campaigns that advocate anti biotics, and increased mortality as a result of increased antibiotic resistance. However, investigators piloting such interventions are already making such calculations. A trial investigating the eff ect of mass administration of azithromycin on the reduction of childhood mortality in Tanzania, Niger, and Malawi is underway. The study's lead investigator, Thomas Lietman acknowledged this trade-off : "We think we will select for antibiotic resistance. However, many of us believe that might be a price worth paying if there is truly a reduction in childhood mortality." 213 The investigators will carefully monitor the development of antibiotic-resistant diseases in the target communities. Lietman notes that in communities treated for trachoma, azithromycin resistance dissipated within 2 years of mass administration ending. Moreover, azithromycin is seldom used in sub-Saharan Africa, and resistant infections remain susceptible to many classes of other antibiotics. The unanswered question is whether this picture of infection will remain true in Africa?
The lessons learnt from a mass campaign diff er from those gained from the treatment of episodic illness. However, the episodic treatment of bacterial infections also needs infrastructure for eff ective delivery. Treatment of acute rheumatic fever to prevent carditis and the sequelae of valvular lesions includes secondary prophylaxis with antibiotics. Adherence to the regimen of monthly, intramuscular injections might best be delivered with a control programme, equipped with a central register, a supply of benzathine penicillin G, and appropriate outreach. Additionally, the plans underway for eradication of yaws might include a diagnostic test for Treponema pallidum and allow for targeting an oral dose of azithromycin to those individuals infected. 214 The challenge in all these eff orts will be to scale-up antibiotic use but to minimise drug resistance from unnecessary or inappropriate use.
Monitoring and assessment of access and excess
Successful antibiotic stewardship programmes need eff ective feedback loops to be established in health-care
The Lancet Infectious Diseases Commission systems and mobilisation of data as triggers for follow-on action. Taking stock of these programmes, quality measures, such as time to fi rst antibiotic for a patient with community-acquired pneumonia, are useful. Some have argued such programmes should be assessed on outcomes, not just process measures. Although relating specifi c measures causally to antibiotic stewardship programmes can be challenging, infection-related mortality, hospital length of stay, readmission rates, C diffi cile infection rates, and antibiotic resistance levels can be useful outcome dimensions to track. 215 Just as vital signs like blood pressure, heart and respiratory rate, and body temperature give a snapshot of a patient's illness, select quality measures can give a similar picture of how eff ectively an intervention is tackling antibiotic resistance in the healthcare delivery system. Data from such surveillance can provide useful feedback to antibiotic stewardship programmes, which can be redesigned to take stock of positive, negative, intended, and unintended eff ects highlighted in thorough monitoring and assessment.
Trends of antibiotic use can be mapped, 216 and perhaps the discovery of regional or local diff erences might encourage responsible parties to act. However, linking surveillance to action can be challenging. The Institute for Healthcare Improvement applies a continuous quality improvement approach, consisting of plan-do-study-act in its work. 217 To tackle antibiotic resistance, collaborations involving like-minded groups can encourage the sharing of such continuous quality improvement lessons among local innovators. A process of collaborative improve ment among institutions facing similar diffi culties was the hallmark of the Institute for Healthcare Improve ment's breakthrough collaborative. 218 As part of its state-wide Antibiotic Stewardship Program Initiative, the California Department of Public Health has also set about developing collaborations among hospitals that share common challenges.
219
Achieving access without excess
For the 1 billion people who live on less than $1·25 a day, a full course of antibiotics paid for upfront might not be aff ordable. The balance of access and excess poses an important ethical question as to who should access antibiotics, under what circumstances, and who should make these decisions if they should not be left to the discretion of users, or even prescribers and providers. If antibiotics are treated as a non-renewable resource, access to both new and existing products needs to be thought about carefully.
Taking a systems approach, tackling antibiotic resistance involves intervention at the level of innovation, dissemination and introduction, scale-up and implementation, and monitoring and assessment. Every stage off ers the opportunity to re-engineer the system. To develop new antibiotics, fi nancing models that delink research and development investment from revenue returns are needed. The productive focus for a grand challenge competition could also be the eff ective development and deployment of technologies complementary to antibiotics, notably diagnostics. To disseminate and introduce these tech nologies, anti biotic stewardship might have to go beyond audit and feedback to realignment of incentives. This might also require strategic points for intervention beyond providers, prescribers, and patients, such as at the level of procurement of antibiotics, to be found.
The scale-up and implementation of these inter ventions needs infrastructure, not unlike that of mass administration campaigns, but as exemplifi ed in eff orts to treat acute rheumatic fever, these might need longer term commitments to tracking and follow-up of patients such as in a central registry. Scaling up is also associated with rethinking how incentives work when moving from individual to collective action. New institutional arrangements might be needed to pool and share the costs and benefi ts of these interventions across providers, insurers, or drug companies. Finally, monitoring and assessment requires eff ective feedback loops that transform surveillance into follow-on action. Learning collaborations of like-minded individuals or institutions are one promising approach to motivate change and to share lessons from such eff orts.
Access to new antibiotics will need to be controlled through strong regulatory, procurement, and distribution oversight while existing products will need to be protected and their shelf-life extended through coherent and inclusive approaches to antibiotic resistance. Suggested solutions to this major issue lie in inter ventions aimed at re-engineering the delivery system. Public health services can partner with and actively promote accredited drugdispensing outlets, where rational use might be strictly audited; rational use might be enabled through vouchers delivered through mobile-phone-based money transfers. Various approaches to ensure that the full course of antibiotics is taken, not just dispensed, need to be piloted. These scenarios are only examples of system-wide approaches that aim at fi nding the right balance between access and excess.
Part 6: Challenges of antibiotic resistance in weak health systems An underestimated burden
Over the past decade, antibiotic resistance has risen alarmingly worldwide. 220 Among the key players, including global health donors, pharmaceutical companies, technical agencies, and governments, 221 patients and physicians have the strongest eff ect on resistance rates, because selection and spread of resistant organisms is mainly a local process based on practices in individual hospitals and communities. 222 In LMICs with weak health systems, the eff ect of antimicrobial resistance on health and economics is largely underestimated and incompletely understood. At least two-thirds of childhood mortality is related to 
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infections, and children are therefore probably more vulnerable than are adolescents and adults. 223 The increase in resistant strains among bacteria causing some of the commonest childhood infections (eg, newborn sepsis, meningitis, pneumonia, diarrhoea, and typhoid) can make clinical outcomes worse and render fi rst-line empirical antibiotic regimens ineff ective.
Therefore, the challenge lies not only in the use of existing knowledge to make antimicrobial resistance a national health priority, but also in the implementation of customised containment strategies. 90 These strategies must, however, successfully integrate scale-up of proven interventions at the service delivery level with a sustainable self-evaluation process whereby action plans are reviewed and revised on the basis of collected evidence. 224 
Antibiotic resistance in priority pathogens
Neonatal sepsis
Studies of newborn sepsis from Bangladesh, Ethiopia, Nepal, Tanzania, Cameroon, Ghana, India, Nigeria, Pakistan, Yemen, Vietnam, Philippines, and Egypt, 40, [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] support trends in pathogens and resistance highlighted by Waters and co-workers 14 and Zaidi and colleagues. 236 The high proportion of resistance among Entero bacteriaciae (Klebsiella spp and E coli), the leading cause of newborn sepsis in developing countries, to ampicillin, gentamicin, ceftriaxone, and ciprofl oxacin, is concerning. Neonatal nurseries in some LMICs report meticillin resistance rates of 17-28% in S aureus isolates. 40, 216, 237 Similarly, Lubell and colleagues 238 recorded poor susceptibility to almost all commonly used antibiotics in pathogens such as S aureus and Klebsiella spp. Without rigorous evidence, most clinicians agree that 90% susceptibility or higher of potential pathogens to antibiotics in critical care settings like neonatal intensive care units, and 80% or higher in non-critical health-care settings, is acceptable.
Pneumonia and meningitis
Streptococcus pneumoniae, a leading cause of communityacquired pneumonia and bacterial meningitis in children is increasingly resistant to macrolides, third generation cephalosporins, and fl uoroquinolones. Although penicillin non-susceptibility of S pneumoniae (PNSP) does not seem to aff ect outcome of antibiotic treatment in patients with pneumococcal pneumonia, 239 PNSP might be of great clinical signifi cance in deciding treatment options for life-threatening infections such as meningitis. Prevalence of PNSP ranges from 0% in Pakistan 240 to 44% in Algeria, 241 amoxicillin resistance from 20% in Algeria, Morocco, and Tunisia, 242 to 46% in Malta, 241 and cefotaxime resistance from 8% to 17% in North Africa. 242, 243 Macrolide resistance is as common as 33% of isolates in Venezuela and 38% in Mexico. 244 Fluoroquinolone resistance is found in 3% of isolates in Pakistan 240 and up to 24% in Bangladesh. 245 Dual nonsusceptibility to both amoxicillin and erythromycin was reported in 30% of isolates in one North African cohort. 242 
Diarrhoeal pathogens
Vibrio cholerae, salmonella, shigella, E coli, and campylobacter accounted for 500 000 diarrhoeal deaths in 2010. 246 Cholera is still a public health priority in most LMICs; however, resistance to the recommended antibiotics (co-trimoxazole, chloramphenicol, sulphonamides and nalidixic acid) has been reported from countries in South Asia and Africa. [247] [248] [249] [250] [251] In most of subSaharan Africa and Bangladesh, resistance to cotrimoxazole and furazolidone is increasing, whereas resistance to tetracycline fl uctuates from year to year. [252] [253] [254] Resistance and reduced susceptibility against tetracycline, ciprofl oxacin, and azithromycin have also been reported, 248, 255, 256 suggesting the importance of epi demiology to guide treatment.
In LMICs, Shigella fl exneri is the commonest cause of bacillary dysentery in children younger than 5 years. Resistance to ampicillin, tetracycline, co-trimoxazole, and chloramphenicol is common in developing countries. 257 In Africa and Asia, resistance against ciprofl oxacin-the WHO recommended antibiotic for bacillary dysentery in children-rose from 0·6% to 30% over 10 years. 258 Further, reports of emerging resistance to second-line antibiotics such as third-generation cephalosporins and azithromycin are of great concern. 259 Increased resistance to fl ouro quinolones and macrolides is also being reported for campylobacter. Ciprofl oxacin resistance rates range from 65% to 88% in Bangladesh, 260 whereas rates of resistance from African countries range from 5% to 38%. 257, 261 Antibiotic use in veterinary medicine can cause fl uoroquinolone resistance in campylobacter. 262 Multidrug resistance (to ampicillin, chloramphenicol, and co-trimoxazole) in S enterica serotype Typhi (S typhi) is associated with increased severity and high case fatality rates of typhoid fever. 261 Fluoroquinolones, macrolides, and cephalosporins are the second-line, albeit costlier, regimens for treating typhoid fever. However, fl uoroquinolone resistance is increasing in India (44%) and Pakistan (58%), and susceptibility is decreasing in Congo (15%) and Cambodia (80%). [263] [264] [265] [266] In Kenya, 267 more than 77% of the S typhi were multidrug resistant, much higher than the reported 52% in Ghana 268 and 29% in Egypt. 263 Additionally, the proportion of S typhi in Kenya that are multidrug resistant and resistant to nalidixic acid with decreased susceptibility to fl uoroquinolones had risen from 1% in 2000 to nearly 25% in 2008.
Surveillance for resistance trends, monitoring rational use of antibiotics, and development of clinical management guidelines to standardise treatment can curtail development of resistance against the remaining mainstay of treatment, third-generation cephalosporins.
In sub-Saharan Africa, non-typhoidal salmonella are the dominant contributors to invasive bacterial disease. These bacteria are the second commonest cause of neonatal meningitis and the third commonest cause of bacterial meningitis in children older than 2 months in Malawi and Kenya. 269, 270 However, data from some reports suggest
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S typhi is the main serotype in Africa. 267, 271 Multidrug resistance and decreased susceptibility to fl uoroquinolones are now widespread among non-typhoidal salmonella, causing invasive bacterial disease in Kenya and Malawi, [272] [273] [274] and other parts of sub-Saharan Africa. [275] [276] [277] This situation poses a major challenge to treatment and management of disease. In a study from the Democratic Republic of the Congo, 278 rates of multidrug resistance varied from 37% to 80% between diff erent provinces. 10% of the S typhimurium strains isolated from Kinshasa were also resistant to azithromycin. Recently, a very high rate (48%) of cephalosporin resistance has been reported from India, especially in S enterica serotype Agona.
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Risk factors for resistance in childhood disease pathogens Antibiotic misuse
User-related factors such as self-medication, noncompliance, misinformation, and advertising pressures in combination with other factors such as ignorance, lack of education, and inaccessibility to health care and diagnostic facilities, are the major drivers of resistance. Poverty compounds the problems, because patients do not have access to clean water and hygiene and are at an increased risk of acquiring infections. Individuals living in poverty also have poor baseline nutritional status to fi ght off infections and are at risk of treatment termination due to aff ordability issues. 280 Other factors relating to health-care providers that may lead to inappropriate prescribing include insuffi cient training, unprofessional conduct, and paucity of diagnostic facilities, leading to incorrect selection of antibiotics. 280 Inappropriate prescriptions resulting from economic incentives off ered by pharmaceutical companies and inaff ordability of appropriate dose and duration of antibiotic regimens perpetuate a vicious circle of suboptimum treatment leading to antimicrobial resistance. Another cause of antibiotic misuse among prescribers and patients is lack of awareness of the health priority status of antimicrobial resistance among every tier of health-care personnel in developing countries. 280 The highest burden of deaths caused by infectious diseases is in south Asia and sub-Saharan Africa. 232 Countries in these regions also report a high prevalence of multidrug-resistant pathogens with poverty of resources contributing to poor containment of resistant organisms in hospital and community settings, 13 and inadequate training of prescribers and laboratory personnel, 280 contributing to rising resistance through inappropriate empirical antibiotic choices, and laboratory diagnostics. 224 
Quality of antibiotics
Poor countries suff er from lack of regulations for pharmaceutical products, leading to availability of counterfeit and low-quality antibiotics. Use of these ineff ective antibiotics amplifi es resistance and leads to purchase of more potent and expensive antimicrobials to treat resistant strains. 100 Policies for appropriate supervision by regulatory agencies are needed to control the sale and supply of expired and counterfeit drugs.
Lack of antibiotic stewardship and poor infection control
Absence of antibiotic stewardship is associated not only with emergence of resistance, but also with poor outcomes for patients. 281, 282 Apart from appropriate laboratory infrastructure, both stewardship and infection control require teams of a clinical infectious disease physician, clinical pharmacist, and committed hospital administration, which are scarce in LMICs.
Furthermore, insuffi cient infection control surveillance systems within hospitals in LMICs 12 with inherent problems (eg, overcrowding and insuffi cient equipment and trained personnel) leads to spread of nosocomial infections and even outbreaks caused by resistant pathogens. 13 This scenario has huge fi nancial implications for developing countries and can lead to exponential increase in treatment costs besides increase in morbidity and mortality. 12, 283, 284 These resistant pathogens become a commensal reservoir of resistant genes and are spread to the community through unsafe water and poor sanitation. A history of hospitalisation is an important risk factor for acquisition of resistant infection in family members. 284 Infection control and antibiotic use are inter-related and the individual contribution by each of these factors is diffi cult to seperate. 285 
Paucity of surveillance information
Surveillance data are essential for providing information on trends and magnitude of resistance. Unfortunately, timely availability of such data from developing countries is scarce. 286, 287 Causes of this data lag and lack include technical constraints such as non-existence of data collection and analysis infrastructure, poor laboratory infrastructure, and weak leadership and governance to recognise resistance and its public health (clinical, fi nancial, and pharmacological) implications. Absence of essential epidemiological data leads to delayed or suboptimum revisions in guidelines, and strengthens the vicious circle of injudicious use of antibiotics by prescribers on the basis of anecdotal or non-evidence-based experience. 287 Local antibiograms with pathogen-specifi c susceptibility data are crucial in choosing the best empirical antibiotic in resource-constrained settings 287 and are heavily rely on quality-assured laboratory support and an intact information system.
Paucity of leadership and governance
Without appropriate oversight, policy makers are unable to assimilate known information about global and regional drivers of resistance and its public health implications or to recognise the problem as a national health priority. As a result, policy makers will struggle to propose and implement sustainable, multidisciplinary, and multitier (pharma ceuticals, food and agriculture, human resources, fi nancing, and information systems) strategies that link
The Lancet Infectious Diseases Commission science to practicality. [288] [289] [290] Corruption within health systems is of particular importance in LMICs where it can lead to siphoning off of smaller and therefore more precious health budgets. Poor record keeping and general human-resource mismanagement further add to inaccurate burden estimation. Furthermore, because of the lack of transparency and accountability, countries with the most need might miss out on opportunities to attract donors and strengthen their health systems.
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Combating antimicrobial resistance
An eff ective strategy to combat resistance needs action and involvement of individual institutions that commit to implementation of antibiotic stewardship programmes, invest in their development and operation, train existing or employ essential staff , and maintain relevant records. 220, 221 In countries with weak health systems, hurdles such as insuffi cient funds, inadequate infrastructure and management, shortage of trained personnel, non-existent or poorly implemented infection control policies, and poor surveillance records 292 need to be addressed and overcome. Although control and containment strategies should mainly target individual hospitals and communities, vision and direction should come from the platform of national health ministries. In 2012, medical societies in India put together an implementable road map for resistance containment in the country that pushed for central coordination and implementation support from the government. 293 Therefore, physicians can play an important part in advocacy for containment of resistance and give relevant technical input to a national taskforce. In addition to setting national objectives and goals, functions of the taskforce can include seeking and maintaining global partnerships with potential funding agencies, engaging relevant ministries (agriculture, pharmaceutical industry, information, and education) for support functions, regular customisation of the national antibiotic policy by review and feedback of surveillance data, and pushing for legislation through advocacy. 87 Taskforces can customise available guidelines prepared by local and global experts to fi t individual country contexts. 220, 294, 295 Some success stories from LMICs are encouraging. For example, Burkina Faso and Ghana have created confi dence in global donors, inviting external investment in strengthening systems through committed steps that ensure transparency and accountability in management of public fi nances. 296 Honduras and Chad have used public expenditure tracking surveys to understand how resource fl ows in health systems can be abused. 297, 298 In Mexico, a transparency and access to public information law was successfully implemented in 2002, 299 which paved the way for a citizens' audit into funds redirected from an HIV programme. 300 For other countries such as Pakistan, with the most deterioration reported between 1996-2004, 301 deeper systematic reform could be the answer. 295 Championship at the central level is essential to improve cash fl ow into resources like information systems, laboratory infrastructure, and personnel training.
Systems-support guidelines provide information on appropriate indicators (ie, scientifi c, population, and systems data) for development of antibiotic resistance information databases. 302 The central taskforce must standardise laboratory reporting of resistant pathogens in an electronic programme through liaison between local microbiologists, infectious disease specialists or general clinicians, and information technology experts. Fraser and colleagues 303 reported successful implementation of electronic medical systems as pilot projects in, Haiti, Malawi, and Peru. This capacity building can be taken up as a systems-strengthening project with partial commitment from both individual governments and competitive bidding for external funding. The task force needs to provide software programs to hospitals across the country so that nosocomial and community pathogens can be identifi ed and resistant clones tracked at district, provincial, and national levels. 87 Taskforce fi nances need to match annual agendas. Global experts, local legislators, fi nancial experts, epidemiologists, public health experts, and private-public sector representatives can be stakeholders in the fi nance and ensure the best use of resources for evidence-driven strategies. Optimum coverage of BCG, diphtheria, pertussis, Haemophilus infl uenzae b, pneumococcal and measles vaccines, now available in most developing countries with Global Alliance for Vaccines and Immunisation (GAVI) support, can contribute to reduction in antibiotic resistance by reducing disease occurrence and thus the use of millions of doses of antibiotics. 304, 305 Public-private partnerships have been suggested as a possible way for non-GAVI eligible countries to bridge the vaccination gap. 306 Imperfect vaccines targeting drug-resistant pathogens have also been suggested as a method to improve the population-wide proportion of drug-resistant versus drug-sensitive strains. 307 Overall use of antibiotics can decrease with diagnostic information. 52 Validation of point-of-care tests for respiratory tract infections, the leading cause of overprescription of antibiotics in children, might be an important step towards improved antibiotic use. 135 Education and training incentives to health-care providers such as prescribers and dispensers in the community and members of infection control and therapeutic committees within hospitals have been recommended. 224 Direct education of patients also improved antibiotic compliance and decreased use of unindicated drugs in Peru. 224 Training at all levels of a multilevel health system should be in conjunction with systems-strengthening steps such as provision of necessary resources (eg, printed guidelines, data systems, and reporting protocols).
Important steps to contain resistance at the primary health-care level include country-wide scale-up of integrated management of treatment protocols for neonates and children, 308 
Part 7: Improving the interface between academia and the pharmaceutical industry The need for new antibiotics
Antibiotic discovery has stalled, but we do not know how to restart the engine. The golden age of antibiotic discovery between 1929 and the 1970s saw more than 20 new classes of antibiotic reach the market. 310, 311 Since then, only two new classes have reached the market. 312, 313 Analogue development seems to be drying up because the number of analogues that can be derived within one class is fi nite. 1 The attitudes of regulators and payers have also discouraged development of so-called "me too" products. The net result is that the worldwide antibiotic pipeline for new antibiotic classes active against highly resistant Gramnegative bacteria is almost dry; [314] [315] [316] the only novel class in early clinical development has recently been withdrawn. 315, 317 However, the situation for Gram-positives is better because compounds from two new classes have been marketed in the past 15 years (linezolid in 2000 and daptomycin in 2006), 312, 313 and one more is in the pipeline. 315 Meanwhile, new analogue development and com binations of old antibiotics with, for example β-lactamase inhibitors, are struggling to keep pace with the relentless emergence of antibiotic resistant bacteria with new resistance profi les. In our view, if the world is to return to the golden age, it needs to make new classes of antibiotics and will need up to 20 new classes to reach the market within the next 20-60 years. 310 Because resistance arises to all antibiotics, whether they are a new class or an analogue of an old class, it could be argued that new classes are not needed, only compounds that target highly resistant pathogens, including those resistant to other drugs in its class.
We believe that, eventually, chemists will run out of options if no new classes are marketed because the chemical options for variations within one class structure are fi nite. Some Gram-negative bacteria such as NDM-1 producing K pneumoniae are already resistant to almost all antibiotics, including carbapenems; chemists struggle to fi nd treatments for some highly resistant bacteria with the range of available classes. Ideally, new classes should be rolled out gradually and evenly over an extended period, and the new discovery and development should be paired with a better and more eff ective stewardship approach to protect existing drugs and those that are newly developed. However, if new classes of antibiotics are rolled out too slowly, millions of people are likely to die because resistance will arise to all new antibiotics over time. Gaps in coverage against highly resistant bacteria have already appeared and there will be larger gaps in the future if more antibiotics are not produced quickly enough. Furthermore, the discovery of new classes of antibiotics is unlikely to be steady and even. After all, it might be impossible to discover and market enough new analogues or classes to keep up with the continuous emergence of antibiotic resistance, especially in Gram-negative bacteria.
The need for new antibiotics is obvious, but the urgency varies. In hospitals, especially in intensive care units in some parts of some countries, there are dangerous levels of highly resistant bacteria. 318 In other countries, highly resistant bacteria are less common, especially in the community. 319, 320 So the global response to antibiotic resistance, in terms of eff orts in antibiotic discovery, is likely to vary with percieved threat.
Why has antibiotic discovery stalled?
After the end of the golden age, academic bacteriology moved away from antibiotic discovery. There was a view that infectious diseases had almost been eliminated and that industry would market an endless stream of antibiotics. Initially, in the 1970s and 1980s, the pharmaceutical industry did produce a stream of antibiotics. These were analogues but not new classes. In retrospect, we believe that this was a fundamental mistake, because, although analogue development is low risk compared with novel class discovery and development, analogues eventually become more diffi cult to come by. The ingenuity of the medicinal chemists is overcome by nature, in the form of relentless emergence of new forms of bacterial antibiotic resistance. Although resistance arises to fi rst-inclass antibiotics after marketing, a new class of com pounds widens the opportunities for chemists to create new analogues that target highly resistant bacteria. Unfortunately, industry, encouraged by academia, made a second fundamental mistake, namely to enter genomics on the grounds that this would lead to many new classes of antibiotics-an endeavour that failed. 310 Industry closed many antibiotic research laboratories. As a result, the world is left with a decreasing stock of eff ective antibiotics, an inadequate pipeline of new classes and analogues, a broken antibiotic market, a paucity of antibiotic discovery infrastructure in academia, and insuffi cient infrastructure in industry.
A report 321 commissioned by the Swedish Government concluded that the antibiotics market should have rational intervention, the eff ective life of existing and new antibiotics should be preserved, push-pull incentive
The Lancet Infectious Diseases Commission models should exist, and legal regulatory changes should be made. A high-level conference hosted by the Swedish Government (fi gure 7) 322, 323 concluded that three reasons explain the empty pipeline: scientifi c challenges; regulatory requirements, such as needing superiority or noninferiority trials; and market failure (ie, absence of appropriate incentives to develop medicines for which use will be restricted). The political conclusions made by the EU health ministers, who met after the conference, resulted in an action plan from the European Commission, 324 which is being implemented. This meeting was followed by a global conference in 2010. 325 The Pharmaceutical Research and Manufacturers of America recently asked the FDA for a more fl exible approach to regulation of new antibiotics. 326 The European Medicines Agency has relaxed its guidelines for clinical antibiotic trials in four ways: fi rst, patients can be enrolled in trials after receipt of a dose of previous antibiotic treatment, making enrolment possible; second, organismspecifi c rather than disease-specifi c studies can be done; third, small studies can be used to support approval of antibiotics that treat resistant, critical infections; and fourth, clinical response endpoints can be assessed at testof-cure visits. 327 The Infectious Diseases Society of America (IDSA) has proposed the 10 x '20 Initiative, which calls for the development of ten new, safe, and effi cacious systemically given antibiotics by 2020, but progress remains elusive. 328 Despite this encouraging attention by policy makers and regulators, some are now questioning whether modern medicine can continue in the future without more eff ective antibiotics.
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The need to improve antibiotic stewardship
Under the existing business model, major pharma ceutical companies presumably market products to maximise volume. This is not a desirable situation for new antibiotics. For example, some countries use antibiotics less well than others, thereby increasing antibiotic resistance, which is then carried around the world to other countries. On the contrary, delinkage is needed, in which most revenues should be generated not through sales but through a mixed model of income from push funding (such as through the Innovative Medicines Initiative), pull incentives (such as advance purchase commitments or new market exclusivities), and in-market sales. 325 Furthermore, models for global access at aff ordable prices should be agreed upfront-a fact that emphasises the need for new fi nancing and incentives. The advantage of this approach is that new antibiotics could be put on the shelf until they are needed, and their use could be restricted, thereby prolonging their shelf-life. The disadvantage of this approach is that the pharmaceutical industry might continue to be wary of investment in antibiotic development, although advance purchase commitments or new market exclusivities could off set this. The reason for industry's reluctance to invest is because such restrictions lead to a large reduction in the value of the antibiotic at discovery. The Offi ce of Health Economics 330 has estimated that, with restrictions, the net present value of antibiotic to a drug company is minus $50 million, whereas a new musculoskeletal drug, without restrictions, is worth $1 billion. 327 The Generating Antibiotic Incentives Now (GAIN) Act has recently been introduced in the USA and allows prolonged exclusivity 327 and other provisions. This act could increase the value of antibiotics to companies, thereby encouraging com panies to enter the fi eld; however, it does not address the issue of stewardship. If a drug is to be used as a last resort, what good are market exclusivity rights?
The IDSA has suggested 331 an alternative way forward that could provide an increased unit price for new antibiotics and reduce the cost of clinical trials, thus providing economic incentives for investment while restricting use. This proposal calls for a new regulatory approach, the limited population antibiotic drug provision, through which antibiotics could be approved after small, low-cost clinical superiority trials that target highly resistant bacteria that potentially cause lethal disease. The antibiotic would receive a very narrow label that would help to protect it from overuse. Although if introduced, this new regulation could both encourage investment and restrict use, the high unit price would need to be addressed for global access, especially in developing countries.
The academia-industry interface
The infrastructure of antibiotic discovery in academia and the pharmaceutical industry has fallen to a dangerously low level. A prolonged loss of skills in both sectors means few people have experience of antibiotic discovery, especially of new classes. If a university or a company has no people engaged in antibiotic discovery, it is unlikely to produce new ideas in this area. 
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In academia, emphasis is placed on new ideas. In our experience, there is no shortage of new ideas in universities, although there needs to be a critical mass of people in an institution who think about antibiotic discovery. However, translation of these ideas into a marketed antibiotic is diffi cult, time-consuming, and expensive. Universities and other institutions try hard to address the translation of basic research ideas into real products. This issue is sometimes addressed by encouragement of academics to patent their ideas. Most ideas do not progress much beyond this stage because there are not enough entrepreneurs or companies willing to take on high-risk projects. This gap needs to be fi lled.
Equally relevant is an opportunity to repurpose existing compounds and those that were discontinued from development with new scientifi c knowledge. Without patents and other market exclusivities, few incentives exist to invest in projects to bring back old antibiotics, or to test new combinations or regimens.
New ideas for antibiotic discovery also come from small and medium sized enterprises (SMEs) in the area. Ideas originate from academia, other companies, or from the SME itself. Translation of ideas into preclinical antibiotic development is something that such enterprises often do well, and some progress into early stage clinical trials. In our view, there is a need for many more SMEs in antibiotic discovery. A new grant-giving system is needed, and a new system of loans for SMEs in this area is also necessary. Infrastructure to bring these companies and academia together is needed at the level of those who are actually associated with research and development of antibiotics. This organisation should be at national and international levels.
In the golden era of antibiotic discovery, major pharmaceutical companies were the home of new ideas, development, and marketing. The huge success of antibiotics in shaping modern medicine is mainly a result of the eff orts of these companies. Unfortunately, those days are over. Ideas for new drugs, not just new antibiotics, are too few to support major companies. However, phase 3 clinical trials are so expensive (the average cost is $70 million per trial) 332 that major companies will usually need to be involved in antibiotic drug development. These companies become included in antibiotic development by in-house eff orts, collaborations with academia, buying or investing in SMEs, or mergers with other large pharmaceutical companies. Expansion of collaboration between major pharmaceutical companies and academia is needed.
New business models Antibiotic recovery plan
The existing resource of antibiotic discovery in academia and industry is too restricted to be eff ective. An interface between two organisations, each of which has inadequate antibiotic discovery, is not going to succeed. The infrastructure of academia and industry needs urgently to be rebuilt, which would be expensive and the responsibility of industry and governments. Because antibiotic resistance is believed to be as serious as climate change, governments should take appropriate action to address the issue. Coates 333 suggested that the European Commission sets up an antibiotic recovery plan, of a similar type to the Marshall Plan in 1948. Other major governments (eg, Japan and the USA) should also fund their own plans. Indeed, the USA has the elements of such an antibiotic recovery plan, already reasonably well funded, a public-private partnership mechanism akin to the Marshall Plan, which is called the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE). This consists of many agencies of the US Federal Government, including National Institute of Allergy and Infectious Diseases, Biomedical Advanced Research and Development Agency, and several Department of Defense agencies. This model is in action, as evidenced by various recently announced multimillion dollar investments. This initiative should be welcomed; however, it has not yet produced the marketed antibiotics that are needed, especially against Gramnegatives, perhaps because of insuffi cient time. Additionally, this initiative is probably insuffi cient to bring enough antibiotics to market for the entire world. A high proportion of loans and grants from governments, say 60%, would be invested as loans in the antibiotic discovery industry, most of which would be SMEs because novel ideas increasingly come from smaller companies. The loans would be administered by a bank with the revolvingdoor model. 333 Collateral would be provided by government and interest rates should be very low. However, recipient companies would need to repay the loans to the government. The money could then be lent to another company in the antibiotic discovery business. This would leave 40%, which would be used to fund grants to universities, SMEs, and major pharmaceutical industries, and pay down debt.
Pharmaceutical industry collaboration
The Innovative Medicines Initiative, funded by the European Federation of Pharmaceutical Industries and Associations, is the biggest public-private initiative in Europe. It is distinct from the EU Framework Programmes and aims to accelerate the development of better medicines for patients. The initiative seeks to improve collaboration between industry and academia, which has been identifi ed as a potential way forward for some years. 334 40 projects are in motion that cover many areas of medicine including antibiotic resistance (eg, COMBACTE and PreDICT-TB). Further Innovative Medicines Initiative funds will be targeted at antibiotic drug discovery in the New Drugs for Bad Bugs programme, if these funds were to be available at early stages of antibiotic discovery that could have a substantial eff ect.
The Innovative Medicines Initiative is dominated by major pharmaceutical partners and is run along the lines of grants from the European Commission, which means The Lancet Infectious Diseases Commission that deliverables are set at the beginning by the partners. The strength of the Innovative Medicines Initiative is its connection with major pharmaceutical companies, which means that drug development is emphasised; its weakness is that it can only fund projects that are already underway, and might create intellectual property challenges arising from collaborations between public-private partnerships, academia, and industry. The initiative does not solve the root of the antibiotic discovery problem-too few novel class and analogue candidates in early stage clinical development. Other collaborative translational research models include a new NIH centre in the USA 335 and Cancer Research UK, 336 but these are not focused on antibiotic discovery.
Charitable organisations
The Bill & Melinda Gates Foundation has led the way in antibiotic development, especially for tuberculosis. Bedaquiline, which has been supported by the foundation was marketed in December 2012 for highly resistant tuberculosis, 337 is the fi rst new drug to be launched for the disease in 40 years. This is a model that could also be used in development of drugs for Gram-negative and Grampositive bacteria.
Academia-industry collaboration
The Innovative Medicines Initiative is just one example of academia-industry collaboration. Although optimised for development, the predetermined delivery of grants is, in our view, too rigid to stimulate research ideas. Other models include embedding an SME in academia. This can work well at the research idea end of the scale, but needs a robust legal agreement between the SME and the academic institution, and an understanding of industry, which is not always present in academia.
Not-for-profi t organisations can also play a part in the promotion of collaboration. For example, Antibiotic Discovery-UK 338 was set up in 2012 to bring together universities and SMEs interested in antibiotic discovery. This is simple to set up, by organising meetings of academics and industrial workers who have experience in antibiotic discovery, development, and market authorisation. It is a low cost way of starting collaborations that can be advantageous when applying for funding from grant-giving bodies. If other countries were to use this model, representatives of each country could then formeg, Antibiotic Discovery-Europe or America. Antibiotic discovery with world coverage would also be a low cost model. Inevitably confl icts of interest will occur, and legal contracts may be required to prevent industry sponsorship from slowing publication of results, restricting the sharing of fi ndings, or suppressing reporting of adverse drug reactions.
Only now is the awareness and urgency of the problem of antibiotic resistance reached a level that a new sustainable global system can be built. For tuberculosis, malaria, and leishmaniasis, Open Source Drug Discovery is a good example. The organisation was founded in 2008 and seeks to provide aff ordable health care to developing countries. It is led by the Council of Scientifi c and Industrial Research India team with more than 7500 registered users from more than 130 countries around the world who engage in open access drug discovery-making it the largest collaborative group in drug discovery in the world. The idea is to discover and develop drugs with public funding. An example of its activities is GlaxoSmithKline making 177 potent noncytotoxic antituberculosis hits publicly available. 339 If successful, this consortium could help to discover cheap antibiotics, presumably via the generic market route. Under present regulatory constraints in developed countries, it would be diffi cult to raise suffi cient money from governments for late-stage clinical trials in, for example, Gram-negative bacterial ventilator-associated pneumonia, but the regulatory landscape might change to accommodate much cheaper routes for antibiotics to reach the market.
Another global model is Medicines for Malaria Venture (MMV), a not-for-profi t public-private partnership, set up in Switzerland in 1999 with the objective of aff ordable antimalarial drug discovery and development. 
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A new funding model has been developed by the Global Fund to Fight AIDS, Tuberculosis, and Malaria. The fund operates as a fi nancial instrument, not an implementing entity, and supports programmes from national plans. Proposals are assessed by an independent review process. The advantage of such a fund is that the money raised is spent on programmes relevant to partner countries. The fund is not focused on antibiotic resistance, but this could change because some developing countries have a big problem already with highly resistant bacterial infections, including tuberculosis.
Could the World Bank have a role? The World Bank provides loans to developing countries for capital programmes; its goal is to reduce poverty and can provide loans for research and development, which could include antibiotic resistance.
Construct an antibiotic discovery programme?
On the grounds that one model is unlikely to be enough, could we combine many diff erent models and create an eff ective global antibiotic discovery programme?
Countries could set up not-for-profi t overarching networks of people involved in antibiotic discovery. These networks would then form the basis of a global network and could give rise to an open source for antibiotic discovery. Collaborations with major partners such as countries and institutions could be modelled on the DNDi. Funding could come from inclusion of antibiotic discovery by charitable organisations such as the Gates Foundation and by the Global Fund and World Bank. Changes to the regulation of antibiotic development for highly resistant bacterial pathogens using the IDSA suggestion of the limited population antibiotic drugs could be used. Alternatively, regulations could be changed towards those that already exist for annual infl uenza vaccines, in which post marketing safety surveillance would be mandatory. Cofunding through the Innovative Medicines Initiative is an attractive solution, but will only work when a fi nancier has been found for the 50% required by the private sector. In addition, a loan system, of the type used in the Marshall Plan, would enable a large number of phase 3 clinical trials, the most expensive part of antibiotic development, to be done. Loans are preferable to grants in the longterm, because once paid back money can be reinvested into drug discovery.
A grand challenge in antibiotic discovery would be one place to start. This idea is based upon the grand challenges used by the Gates Foundation. Grants, be they from government or charity, would be given with a low entry threshold to academia and SMEs that had new ideas of antibiotic discovery. There may be an insuffi cient number of SMEs to cope with the need for new compoundsacademics could be encouraged to set up their own companies and SMEs could be encouraged to embed in universities to foster collaboration with legal agreements to protect both parties.
Preclinical development would be done by SMEs, and would aim to mature the drug to be phase 1 ready. A central facility would need to be set up to provide advice to academics and SMEs about preclinical development. Funding could derive from government loans or grants. Phase 1/2 and phase 2 clinical trials would be done by SMEs funded by loans and grants. The central facility would provide advice about clinical development.
SMEs would usually falter at the phase 3 stage of development, which are often too expensive for such companies. Possible ways forward are to partner with a major pharmaceutical company, or with a large fi nancial institution. Another way is to reduce the cost of trials by using microbiological endpoints, 6 which can make trials up to ten-times cheaper than those using clinical endpoints.
In summary, regeneration of antibiotic discovery could be achieved by collaboration between academia and the pharmaceutical industry. The infra structure of antibiotic discovery in both academia and in industry is dangerously weakened and needs to be rebuilt.
Part 8: Beyond antibiotics-alternative strategies for prevention and treatment
Antibiotics today
Most antibiotic chemical scaff olds in present clinical use were discovered more than 50 years ago. These discoveries mainly came as a result of mining the bioactive chemicals produced by soil bacteria. The large eff ect of these new antibiotics in treating infections and enabling new medical procedures was tempered somewhat early in their use by the emergence of resistant strains of pathogens and eventually their spread, along with their genes, across the globe. 4 Later, many antibiotic scaff olds derived from microbial secondary metabolism were chemically modifi ed to improve effi cacy and circumvent resistance, leading to regular availability of plentiful new medicines to address emerging challenges from increasingly multidrugresistant pathogens.
The ability of the pharmaceutical sector to reliably deliver new drugs to the clinic to address the resistance-mediated obsolescence of old medicines is very limited in the 21st century. A general paucity of investment and activity in antibiotic drug discovery exists, and consequently few new drugs are on the horizon. 340 This fact has frankly taken the public, clinicians, regulators, and politicians by surprise. Where will the new antibiotics come from that are needed to address the growing problem of resistance? Both conventional and non-conventional approaches are needed to address this pressing clinical problem.
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New antibiotics
Once dismissed as old thinking, a renaissance in natural product discovery is needed. We have not exhausted the chemical space of traditional single molecules with potent antibiotic activity and drug potential. However, the days of highly potent, non-toxic, broad-spectrum, and inexpensive The Lancet Infectious Diseases Commission drugs might be over. These were the criteria that traditionally benchmarked antibiotic drug discovery and are increasingly diffi cult to achieve. In fact, the desire for broad-spectrum agents, active against most Gram-positive and Gram-negative pathogens, has selected for drugs with the capacity for serious deleterious eff ects on the human microbiota. The result has been unwanted side-eff ects and, in the emergence of antibiotic associated colitis due to C diffi cile, even increased morbidity and mortality. 342 The clinical reasoning driving the search for broad-spectrum drugs is the fact that very often, the microorganisms causing the infection are unknown to the clinician at the time of presentation. Therefore physicians opt for empirical treatment to cover all the bases, leading to a desire for broad-spectrum drugs. A new focus on very narrow spectrum or even organism-specifi c antibiotics accompanied by advances in molecular diagnostics to guide infectious disease specialists in drug deployment could provide a new, more selective antibiotic arsenal. However, the discovery of such drugs will need new approaches and chemicals in step with innovation in diagnostics and changes to the regulatory frameworks governing new antibiotic approval. 343 The chemical matter and drug discovery strategy dominant in the antibiotic sector over the past 25 years has been focused on synthetic chemical libraries and in-vitro target-based approaches. Although this strategy has enjoyed success in various therapeutic areas, its use in antibiotic discovery is a well documented failure. 344 Modern target-based drug discovery seems to have missed the mark because of an incomplete understanding of the bacterial targets selected and of the chemistry needed for success in the development of antibacterial drugs. However, natural products, in particular from microbial sources, have been an outstanding source of antibiotic chemical scaff olds. More than 25 000 such molecules have already been discovered and the genome sequences of producing organisms have provided a glimpse of a huge potential for new compounds. 345, 346 Re investigation of this bioactive chemical wealth should prove useful, especially with cell-based screens on either multidrug-resistant organisms to avoid identifi cation of known drug scaff olds or strains engineered to favour discovery of desired targets-for example using antisense RNA strategies to deplete key enzymes or pathways thereby sensitising cells to compounds aff ecting privileged targets. 347 The success of the lipopeptide daptomycin (marketed as Cubicin), is an instructive lesson to emphasise some of the above points. 348 Daptomycin is a natural product produced by the soil bacterium Streptomyces roseosporus fi rst discovered in the 1980s at Eli Lilly. Initial exploration of its promise as a new antibiotic was halted because of muscle toxic eff ects. Furthermore, daptomycin had a narrow spectrum, eff ective only against selected Gram-positive pathogens, a deal-breaker for conventional antibiotic development strategies. Nevertheless creative reexamination of dosing obviated the muscle toxic eff ects and increased clinical need spurred by the emergence of MRSA as an important pathogen resulted in reexamination of daptomycin by Cubist, a medium sized pharmaceutical company, and subsequent clinical approval of daptomycin in 2003. Sales of the drug are on track to top $1 billion per year in the near future, showing that even narrow-spectrum natural product agents have the potential to provide excellent return on investment. Indeed, measures such as the GAIN Act, signed into law recently by the US Government, provide for additional market exclusivity and a favourable regulatory framework for new antibiotic drugs. 349 Therefore, with the appropriate chemical matter, clever screens that avoid prevailing chemical scaff olds, and a willingness to forego broad-spectrum coverage for a more limited fi eld of susceptible organisms, there is great reason to be optimistic that traditional single agent antibiotics can continue to be identifi ed and brought to market. However, there are also grounds to be optimistic that alternative approaches to traditional antibiotics can off er alternative strategies for new medicines. These include, but are not limited to, antibiotic adjuvants, antivirulence strategies, and biologicals.
Adjuvants
Compounds that potentiate the activity of antibiotics, antibiotic adjuvants, can increase the effi cacy of drugs in both antibiotic susceptible and resistant pathogens. 350 The combination of antibiotics, often empirically to cover the spectrum of possible infections and to avoid possible resistance, has been a mainstay of infectious disease medicine for decades. Indeed, the fi rst-line treatment of some bacterial diseases, such as tuberculosis, requires multidrug treatment, as do common treatments for cancer and viral diseases like hepatitis and HIV/AIDS. However, combination of antibiotics with non-antibiotic compounds with adjuvant activity is a relatively novel strategy that can reveal unexpected biology and overcome resistance.
Antibiotic adjuvants can take the form of compounds that directly target resistance mechanisms and compounds that exploit chemical genetic interactions that potentiate antibiotic activity. Directly targeting resistance mechanisms is a clinically proven strategy that extends the spectrum of antibiotics by inhibiting resistance and rescuing antibiotic activity. Various inhibitors of Ser-β-lactamases in combination with penicillins have been in clinical use for decades. 351 Important among these is a combination of amoxicillin with the β-lactamase inhibitor clavulanic acid, a natural product produced by Streptomyces calvuligerus, marketed as Augmentin (GlaxoSmithKline). Other similar combinations in clinical use include ticarcillin with clavulanic acid (Timentin; GlaxoSmithKline), piperacillin with tazobactam (Zosyn; Pfi zer) and ampicillin with sulbactam (Unasyn; Pfi zer). Experimentally, clavulanic acid inhibits the intrinsic β-lactamase that renders Mycobacterium tuberculosis impervious to β-lactam antibiotics and thus a combination with meropenem has
The Lancet Infectious Diseases Commission excellent killing activity against this deadly pathogen off ering a new treatment strategy. 352 The β-lactamase inhibitor combinations in current clinical use have little eff ect on strains producing AmpC or ESBLs (fi gure 8). To address this clinical need, the novel β-lactamase inhibitor avibactam in combination with cephalosporins (ceftaroline and ceftazidime) is in latestage clinical trials and is showing great promise. 353 The notion of directly inhibiting resistance elements, thereby rescuing antibiotic activity, is not confi ned to the β-lactam antibiotics. Eff orts to block aminoglycoside-inactivating enzymes 354 and antibiotic effl ux pumps 355 have also proven eff ective in vitro, though none have progressed to clinical trials yet.
Antibiotic adjuvants are not restricted to inhibitors of resistance. In a screen of off -patent drugs for potentiators of the tetracycline analogue minocycline against E coli, S aureus, and P aeruginosa, several non-antibiotic compounds were identifi ed with adjuvant properties. One of these was loperamide (Immodium; McNeil Consumer Healthcare). 356 This compound is a μ-opioid receptor agonist in people. In Gram-negative bacteria (that do not have this receptor), loperamide disrupts the electrical component (Δ) of the proton motive force across the bacterial membrane. The bacteria respond by increasing the pH gradient (ΔpH) to maintain the ATP-generating capacity of the proton motive force. It is this pH gradient that enables tetracycline to enter the cell. Therefore loperamide increases antibiotic infl ux, even in otherwise resistant cells. The combination was highly eff ective in vitro and in animal models of infection, providing a proofof-principle of the adjuvant approach and screening to identify non-obvious drug combinations. Similar screens in pathogenic yeast uncovered unexpected cell-killing synergy between the fungistatic antifungal drug fl uconazole and the selective serotonin reuptake inhibitor sertraline (Zoloft; Pfi zer). 357 In recently published work, 358 the approach identifi ed a new combination of the cephalosporin cefuroxime and the antiplatelet aggregation drug ticlopidine (Ticlid; Roche). Here an unexpected inhibition of TarO, an enzyme essential for early stage wall teichoic acid biosynthesis, by ticlopidine was recorded. This inhibition results in particularly powerful synergy with β-lactam antibiotics that target PBP2 in MRSA, which otherwise is insensitive to cefuroxime. Thus, the combination achieves both suppression of antibiotic resistance and narrow pathogen selectivity, both key attributes of 21st century antibiotic medicines.
The antibiotic adjuvant idea can also be applied to overcome bacterial functions that are commonly associated with drug resistance. In particular, bacteria can adhere to surfaces such as medical devices and epithelial cells, where they continue to grow but become insensitive to antibiotics. These biofi lms are implicated in numerous bacterial infections and are often the reason that antibiotic treatment fails. Several eff orts to combine antibiotics with agents that prevent biofi lms from forming, disrupt them, or otherwise block their antibiotic insensitivity have been reported. 359, 360 Some of these are quite potent in their eff ects in vitro, suggesting that the approach has merit for clinical assessment.
Antivirulence strategies
One of the reasons that antibiotic resistance is such a challenge is that the evolutionary bottleneck of cell death is so stringent, and the numbers of bacteria in one infection are so large that even rare mutational events can result in resistant mutants that break through. Coupled with the ability to receive DNA horizontally from other species or even genera, the massive adapt or die selective pressure steers evolution towards the selection of ever more resistant pathogens. An alternative notion is not to kill bacteria, but rather impair their ability to establish an infection in the fi rst place. These antivirulence strategies have been aided by genetic screens to identify virulence determinants for a number of pathogens. 361 In principle, such virulence targets are less prone to selection for resistance to antivirulence agents, and mutants that do occur are much more likely to be impaired in their ability to cause infection. To the extent that some antivirulence approaches will place a selective pressure on pathogens, one clearly needs to be cautious about the question of drug resistance and virulence. Nevertheless, this approach will benefi t from the fact that antivirulence compounds tend to be narrow in spectrum and this will restrict any selective pressures for drug resistance. Here again, the benefi t of species-specifi c treatment defi nes an imperative for a new generation of antibiotics.
Among the more promising antivirulence targets are quorum sensing, type 3 secretion systems, toxins, and the biosynthesis of glycolipid surface structures. Quorum sensing refers to the production of diff usible small molecules by bacteria that act as autoinducers of various cellular factors at high cell densities. These compounds, such as homoserine lactones produced by Gram-negative The Lancet Infectious Diseases Commission pathogens and small peptides by Gram-positive organisms, trigger various responses including the formation of biofi lms. Inhibition of quorum sensing disrupts this process. Several such inhibitory compounds have been identifi ed that block virulence and quorum sensing in P aeruginosa 362 and S aureus, 363, 364 for example. Bacterial colonisation of tissue is essential to the establishment of infection and interference with this process is a high-quality target for antivirulence compounds. Among the fi rst small molecules shown to prevent virulence was virstatin. 365 This molecule blocks the activity of the V cholerae transcription factor ToxT that controls the expression of TCP, a pillus protein that is essential for colonisation of the intestine. Similarly type 3 secretion systems are extracellular proteins that facilitate bacterial binding to cells and injection of virulence proteins into the cytosol. Several small molecule inhibitors of type 3 secretion systems have been identifi ed including salicylidene acylhydrazides that are eff ective against several pathogens including Chlamydia spp, E coli, S enterica, and Shigella fl exneri. 366 Many pathogens, such as C diffi cile, V cholerae, Bordetella pertussis, E coli, and Bacillus anthracis, secrete extracellular toxins that contribute greatly to virulence. These toxins are often enzymes and have been targeted by screening campaigns to identify inhibitors that attenuate virulence. For example, a series of small molecules have been recently reported that block ADP-ribosyltransferases that are known extracellular bacterial toxins associated with cholera, diphtheria, and pertussis. 367 Disruption of the production of glycolipid surface structures, such as lipopolysaccharide in Gram-negative pathogens and lipoteichoic acids in Gram-positive bacteria, are promising antivirulence strategies. In terms of the former, the essential in-vitro early steps of lipopolysaccharide assembly-namely lipid A and 3-deoxy-D-manno-oct-2-ulosonic acid biosynthesis-have long been indicated as valid targets. However, late steps in lipopolysaccharide synthesis are dispensable in vitro, but are associated with substantial reductions in virulence and increased antibiotic sensitivity. Data from proof-ofprinciple eff orts to fi nd late-step inhibitors 368, 369 suggest that these are targets of high potential. Lipoteichoic acid biosynthesis, a polyanionic glycolipid common to most Gram-positive pathogens has also been the target of recent small molecule screening eff orts that have generated interesting new leads. 370 Additionally, data from feasibility studies in M tuberculosis have suggested that the synthesis of acyltrehalose-containing glycolipids is crucial to host invasion, 371 setting the stage for antivirulence drug discovery eff orts aimed at the cell surface of this organism.
Although antivirulence strategies are expanding the target base for new antibiotics, several challenges are unique to this approach. First, antivirulence agents are probably highly specifi c to individual pathogens and there will be a requirement for great confi dence in identifi cation of the causative agent of disease. In addition to the challenge of diagnosis, to be fully eff ective such agents might need to be provided before infection becomes well established. In some cases-for example, where C diffi cile is a known and serious risk-the argument for prophylaxis will be relatively straightforward, but in other cases, it will not be. Further, these challenges will make clinical trial design especially complex. It is nevertheless imaginable that the fi rst implementation of such drugs may be in combination with conventional antibiotics.
Biological therapeutics
With growing concern over the failing antibiotic drugdiscovery pipeline, there is a great deal of interest and eff orts in progress to investigate alternatives to small molecule drugs. Where biological medical products have had remarkable eff ect on modern medicine, this class of therapeutics is increasingly touted as a viable alternative to antibiotics. Indeed, there has been remarkable success in the area of biologicals (eg, insulin, erythropoietin, monoclonal antibodies, and other engineered receptor constructs) to provide therapeutic options in which there were no or few eff ective alternatives in other areas of medicine. Thus, although biologicals might not form the mainstay of future strategies to deal with multidrug resistance, substantial interest exists in various areas including monoclonal antibodies, modifi ers of the immune system, and age-old phage treatment. We deem the fi rst two of these approaches to be particularly exciting new directions for therapeutics to treat bacterial infection. On the whole, these approaches are not being thought of in isolation of antibiotic treatments but as adjunctive therapies to increase the effi cacy of antibiotic treatment. Eff orts on biologicals in the form of monoclonal antibodies and immune modulators are particularly innovative directions that will benefi t from new understanding of the host-pathogen interactions. These are more long-term solutions to the challenge of antibiotic resistance, but they are driven by the urgent and growing need for new treatments.
The past couple of decades have seen many successful monoclonal antibody-based products introduced in the areas of rheumatology and oncology. Collectively, these eff orts have made the discovery, manufacture, and clinical development for monoclonal antibodies a mature pharmaceutical approach for consideration in an increasing variety of therapeutic areas. This general approach was formerly the exclusive domain of treatments for infection. Passive vaccination, the provision of readymade antibodies to treat infectious disease, was developed by the likes of Paul Ehrlich and Emil Behring in the late 19th century and was the standard of care until it was supplanted by antibiotic treatment. However, today, only one anti-infective monoclonal antibody is on the market-palivizumab for the prevention of respiratory syncytial virus infections in high-risk neonates.
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Modern discovery and development eff orts in monoclonal antibodies for bacterial diseases have been largely focused on bacterial toxins or on cell surface structures. 373 The protective antigen of B anthracis, for example, has been a popular target as are the toxins of C diffi cile. Lipid A and lipoteichoic acid have likewise been targets for monoclonal antibody treatment development, as have surface proteins and carbohydrates from various important pathogens. Although it is relatively early days for these approaches, a consensus is emerging that success in animal models of infection is not always predictive of clinical success. 374 Furthermore, combinations of monoclonal antibodies, perhaps in addition to antibiotic treatment, might be a preferred approach.
Modulation of host immunity is another exciting and emerging approach for the application of biological medicine products to treat bacterial infections. Here, the natural defence mechanisms of the host are targeted for enhancement to derive therapeutic benefi t. Immune modulators under investigation include host defence regulator peptides and agonists of the innate immune system-eg, Toll-like receptors and NOD-like receptors. 375 Innate defence regulator peptides are a particularly interesting subset of these modulators, and are often cationic peptides (10-50 aminoacids) with a high proportion of hydrophobic residues that impart amphiphilic physical properties, are generally membrane-active, and have antimicrobial activity in vitro. 376 Nevertheless, these peptides often have only weak antimicrobial activity under host physiological conditions and have convincing eff ects in modulating the host immune response. The clinical development of such molecules to treat bacterial infections has commonly focused on the antimicrobial activities with subsequent recognition during development of the immuno modulatory properties. 377 Thus, these seem to be com bination treatments with immune and antibiotic activities in one medicine.
Also in this category of immune modulating biologicals are probiotics. A mounting recognition of the role of host microbiota in shaping and modulating our immune systems has led to the therapeutic application of probiotics for various diseases, most notably the treatment of C diffi cile. 378 Such treatments have intuitive appeal to patients and are growing in popularity. Indeed, the science of probiotics remains a mysterious one at present, but the potential is clearly there for this approach and for immune modulation treatments generally. The specialty is well positioned for transformational insights from breakthroughs in mechanistic understanding of how to control the immune system in treatment.
Other antibiotic alternatives that in particular have potential eff ect on C diffi cile infections are the use of microbiome transplantation and the therapeutic application of antibiotic resistance proteins. The transplantation of intestinal microbiomes (also known as faecal transplants) for the treatment of severe gastrointestinal disease caused by C diffi cile infection has promise. A recent systematic review and meta-analysis 379 of available clinical data reported remarkable resolution of disease in most cases, but cautioned that further randomised controlled trails and long-term follow-up are now needed to confi rm the usefulness of the approach. Another creative approach that seeks to prevent C diffi cile overgrowth and infection resulting from antibiotic use is the oral administration of antibiotic resistance enzymes. The biotechnology company Synthetic Biologics is developing a treatment of β-lactamases that when taken orally will degrade β-lactam antibiotics in the intestine that otherwise could degrade the normal microbiome and facilitate C diffi cile infection.
Finally, vaccines remain powerful agents for disease prevention. Their use obviates the need for antibiotic by preventing infection in the fi rst place, and they have been in clinical use for decades. This is an area in which epidemiological studies that identify key circulating pathogens are essential to continuously revise vaccine formulations. The eff ectiveness of the new seven-valent pneumococcal conjugate vaccine in reducing disease burden and consequent unintended selection for the rise of serotypes that are not covered by the vaccine shows the importance of vaccination and continuous monitoring of target organisms. 380 Vaccines directed against organisms for which antibiotic resistance is especially challenging is a strategy that could have great clinical eff ect. Recent eff orts to develop vaccines for important drug resistant pathogens such as MRSA 381 and M tuberculosis 343, 382 are promising, but have yet to generate viable candidates for late stage clinical trials.
Part 9: Call to action
Measuring the extent of the problem and its consequences
The generation of reliable, relevant, and up-to-date information will be essential to respond to the negative eff ects of antibiotic resistance on public health. The poor understanding of the unique features and risks of antibiotic resistance is an important cause for the global complacency paving the way for the present crisis. Few studies have been done on the magnitude of the burden of antibiotic resistance and its contributions to excess mortality to convince policy makers of the need to react. Although antibiotic resistance is undermining the eff ective treatment of many important bacterial diseases with high mortality, especially in LMICs, it lacks the profi le of HIV, tuberculosis, and malaria. Clear information on the health and economic burden of antibiotic resistance is urgently needed to make this complex problem tangible to policy makers. Studies in the EU 383 and USA 36 provide some data, but need to be scaled up worldwide, and the results from such data collection and analysis should be communicated to decision makers, prescribers, dispensers, and the general public. Likewise, a global surveillance system for The Lancet Infectious Diseases Commission antibiotic resistance, including outbreak reporting and an early warning system to detect new resistance mechanisms and their global spread, is still lacking, despite the obvious need of such a system and several proposals for potential models. 384, 385 Absence of essential local epidemiological data also leads to delayed or suboptimum revisions of treatment guidelines, thereby driving the vicious circle of injudicious empirical use of antibiotics by prescribers based on anecdotal evidence or experience without a fi rm evidence base. One large hurdle is the insuffi cient laboratory capacity in LMICs, which need to be strengthened. Meanwhile, sentinel population-based studies are needed to get a rapid global assessment of the scale of antibiotic resistance in key pathogens. Likewise, data for antibiotic use in human medicine, veterinary medicine, agriculture, and horticulture need to be monitored globally and regionally. All countries should set up systems for the monitoring of antibiotic use and comparable units of measurements should be agreed and implemented.
Regulation, rational use, and infection control in human medicine
Antibiotics are diff erent from all other medicines in that the eff ects of their use extend way beyond individual patients. The societal eff ects of antibiotic use justifi es that they should belong to a special regulatory category. Antibiotic use should be strictly monitored and legislation to prevent over-the-counter sales without a prescription enforced, unless this would cause an unacceptable access problem (eg, in rural areas). Financial incentives to prescribers and dispensers leading to irrational use need to be removed. Regular revision of standard treatment guidelines into clear, simple, updated, evidence-based, locally relevant, and accessible documents is essential. Motivational measures include pay-for-performance policy, the audit-feedback mechanism on antibiotic prescribing rates of individual prescribers, and public disclosure on antibiotic prescribing rates of health-care facilities. To reduce patients' perceived need for antibiotics and reduce demand and change social norms, well designed and contextualised educational campaigns should be done. Implementation of basic hygienic routines is still largely absent in many hospitals and health-care settings worldwide. Cultural and other barriers for their implementation need much more study. Infection control interventions need to be reassessed and improved in an era with rapid transmission of multidrug-resistant bacteria and mobile antibiotic resistance genes.
The need for rapid diagnostics
A fundamental obstacle in the management of antibiotic resistance in LMICs is the inadequate capacity and infrastructure to do basic microbiological laboratory analyses. These defi ciencies need to be addressed-eg, by mechanisms similar to the World Bank Challenges exist at every step from ideas for rapid diagnostic tests to uptake by health-care systems. A multidisciplinary, multistakeholder, multiregional, long-term platform should be created with the task of developing a living road map for diagnostic development, identifying the clinical need and associated (technical) requirements in view of market and technology forecasts. The road map should identify the present and future clinical needs and diagnostic requirements, which would enable test developers to bring together appropriate technologies to provide a clinically useful answer. In addition to technology developers (commercial and academic), experts in clinical, statistical, regulatory, behaviour change, and social and health economic sciences, the platform should include the end usersclinical microbiologists, infectious diseases specialists, and other health-care providers-who will base treatment decision on the results of these tests. Factors that aff ect the introduction of new diagnostic technologies and delivery into health systems should be identifi ed, and barriers to acceptance of rapid diagnostic tests addressed. End-users should develop diagnostic algorithms for major infectious diseases where rapid diagnostics could be used to target patients who really need antibiotics. The road map should be developed in three steps: fi rst, reach a consensus about a set of clinical needs and the technologies needed to satisfy those needs; second, provide a mechanism to help forecast technology developments; and third, provide a framework to help plan and coordinate technology development. The creation of target product profi les for novel diagnostic tests would provide useful guidance for industry. Product development partnerships like FIND or PATH could potentially embrace this area of work.
The animal sector and the environment
Antibiotics and antibiotic resistance needs to be seen from an ecological and environmental perspective. Strong local and global partnerships in which policy makers, academia, and professionals from all sectors work together to improve present systems are needed to ensure multifaceted action, sharing of experiences, transparency, and continuous improvement. Un necessary antibiotic use in all sectors needs to be removed and the spread to the For more on ADMER see http:// admerproject.org/ environment minimised. For the animal sector and the environment, we propose the following policy actions. Use of antibiotics, which is unnecessary (eg, for growth promotion) or where alternatives exist (eg, routine prevention) should be phased out. The international organisations WHO, OIE, and FAO should provide a clear defi nition of "unnecessary routine prevention". Governments across the globe should then revise existing legislation or draft new legislation accordingly. The transition should be supported by extension services providing advice on alternatives and on how to tackle potential negative animal health problems. Resources should be allocated for a dialogue between all stakeholders and for monitoring of compliance with the new legislation. WHO, OIE, and FAO should monitor progress All countries should monitor use of antimicrobials for animals in a comparable way. Guidance on collection of data and units of measurement should be agreed on by WHO, OIE, and FAO. Governments should set up systems for data collection and analysis of antibiotic use by species and production type. The pharmaceutical industry, farmers, and veterinarians should contribute by providing access to data. WHO, OIE, and FAO should monitor progress jointly.
The need for antimicrobials in animals should be reduced. WHO, OIE, and FAO, governments, and key stakeholders (pharmaceutical industry, farmers, veterinarians, academics, among others) should work together to identify and implement incentives for development of health-orientated systems for rearing of animals for food production and for development and implementation of other disease preventive measures. Additionally, all key stakeholders should commit to prudent and rational use of antimicrobials. The environmental release of antibiotics from all sectors needs to be monitored and controlled. Strategies need to identify and focus control on hot spots for horizontal resistance gene transfer such as wastewater treatment facilities.
New antibiotics and alternative strategies
The rapid pandemic spread of multiresistant bacteria and the paucity of new eff ective antibiotics is placing patients' safety at risk worldwide. The infrastructure of antibiotic discovery both in academia and in industry is at a dangerously low level and needs to be rebuilt. A new sustainable global model for the discovery, development, and distribution of antibiotics needs be developed in which the private and public sectors work in partnership and the large scientifi c bottlenecks for discovery of antibiotics with new mechanisms of action are solved in collaboration between academia, SMEs, and major pharmaceutical companies. In the EU, substantial public funding for antibiotic research has been put into the Innovative Medicines Initiative, and the Joint Programming Initative on Antimicrobial Resistance is strengthening collaboration within the academic sectors in 18 of the EU member states. These important initiatives need to be moved to structured sustainable global collaboration. Beyond the much needed substantial push funding for antibiotic discovery and development, incentives are needed to secure the rational use of new antibiotics and prevent them from being heavily marketed. Financing models that delink research and development investment from revenue returns need to be developed and piloted. By such delinkage, the return on investment for pharmaceutical fi rms should be divorced from volume-based market sales of antibiotics and access to new antibiotics will need to be controlled through regulation, procurement, and distribution. Such approaches should empower consumers and providers alike to tackle antibiotic resistance as well as ensure that those in need benefi t from aff ordable, eff ective antibiotics.
Intensive research eff orts need to be directed to retain the effi cacy of our present antibiotics by substantial investment in antibiotic adjuvants. Alongside antibiotic research, increased investments need to be made in alternatives to antibiotics. The goal is to encourage researchers and biotech to reconsider the reliance on antibiotics and to explore other means of controlling bacterial infection, such as virulence blockers, monoclonal antibodies, immune modulators, and bacterial vaccines.
Governmental coordination and action
The ultimate responsibility for the provision of equitable and aff ordable access to eff ective antibiotics for those in need lies with national governments. The consequences of antibiotic resistance reach far beyond the human health sector and thus no one governmental ministry or agency can be held solely responsible. National task forces with a broad intersectoral coordinating role, including all relevant stakeholders, with governmental mandate, are needed. Task forces should produce annual action plans and milestones in diff erent areas, such as surveillance, regulation, treatment guidelines, infection control, education, and awareness raising. Health professionals and university academics have an important catalytic role and should engage with community leaders, civil society organisations, and students.
Global governance
The serious threat to public health caused by the rapid loss of antibiotic eff ectiveness calls for global concerted actions. We advocate for a health systems thinking approach in the eff orts to contain antibiotic resistance. Treatment for bacterial infections is a fundamental prerequisite for fulfi lment of health related Millennium Development Goals and access to eff ective antibiotics should be included in the discussions of the post-2015 Developments Goals. We call for a coalition of governments with a strong representation from LMICs that will work with WHO, UNICEF, UN Development Programme, other UN agencies, other international bodies, science academies, development aid agencies, philanthropists, and civil society organisations to develop a global plan to tackle the antibiotic crisis and share responsibilities for its implementation. This governmental coalition should also 
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